Organic compound

PDE1 inhibitors address the recruitment of immune cells to tumors and mitigate immune-related side effects by increasing cAMP levels, effectively inhibiting tumor progression and enhancing immunotherapy efficacy.

JP2024164126AActive Publication Date: 2024-11-26INTRA CELLULAR THERAPIES INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024139639
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-01-07
Filing Date
2024-08-21
Publication Date
2024-11-26
Estimated Expiration
2040-01-07

AI Technical Summary

Technical Problem

Current cancer therapies face challenges in targeting the recruitment of immune cells, such as macrophages, to tumors, leading to tumor progression and metastasis, while also experiencing adverse immune-related side effects from checkpoint inhibitor therapies.

Method used

The use of phosphodiesterase 1 (PDE1) inhibitors to suppress the recruitment of immune cells to tumors and enhance the effectiveness of cancer immunotherapies by increasing intracellular cAMP levels, thereby inhibiting tumor cell migration and reducing inflammatory side effects.

Benefits of technology

PDE1 inhibitors effectively inhibit tumor cell migration and metastasis by disrupting immune surveillance and reducing cytokine release syndrome, enhancing the efficacy of cancer immunotherapies with reduced adverse effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024164126000052
    Figure 2024164126000052
  • Figure 2024164126000053
    Figure 2024164126000053
  • Figure 2024164126000054
    Figure 2024164126000054
Patent Text Reader

Abstract

To provide immune system cells including macrophages and microglia, and pharmaceuticals for suppressing recruitment of other cells to cancer.SOLUTION: The present invention provides a pharmaceutical for suppressing macrophage or microglial recruitment to metastatic cells, comprising a PDE1 inhibitor. Preferably, the pharmaceutical is administered in combination with a checkpoint inhibitor. Preferably, the checkpoint inhibitor is an inhibitor of CTLA-4, PD-1 and / or PD-L1.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The field relates to the use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of cancers and tumors, including inhibiting the recruitment of macrophages and other cells to tumors or cancers, for inhibiting tumor cell migration and preventing tumor metastasis, for complementing and enhancing checkpoint inhibitor therapy, genome editing therapy and chimeric antigen receptor T cell (CAR-T) therapy, for preventing or reversing an immunosuppressive tumor microenvironment, and for reducing side effects (i.e., inflammatory-related adverse events) associated with immunotherapy, including checkpoint inhibitor therapy, and cellular immunotherapy, including CAR-T therapy. [Background technology]

[0002] It is estimated that 90% of cancer-related deaths worldwide are due to metastasis. In most cases, metastatic tumor cells develop ways to evade the immune response and become resistant to therapy. Resistance to cancer therapy can be intrinsic to tumor cells, but is often conferred or enhanced by non-malignant cells that compose the tumor microenvironment (TME). The TME is composed of tissue-resident cells, stromal cells, and other cells recruited by the tumor, thus making it an important hub for tumor regeneration. These cells include endothelial cells, pericytes, fibroblasts, mesenchymal stem cells, and regulatory T (T regThe immune TME may contain a variety of immune cells, including inflammatory bowel disease (IGD) cells, mast cells, neutrophils, myeloid-derived suppressor cells, and tumor-associated macrophages. These cells promote tumor angiogenesis and cancer cell invasion, and / or subvert immune surveillance. Macrophages are one of the most common types of tumor-associated cells. Researchers initially assumed that these immune cells were part of the body's response to reject tumors, and indeed, the primary check on the development of cancer is immune system surveillance and response to the presence of cancer by cells of the innate immune system (e.g., macrophages, neutrophils) and cells associated with the adaptive immune response (e.g., T cells and B cells). However, in some cases, cancers are able to evade and exploit the immune system, so that these immune system cells become part of the tumor's support and defense system rather than attacking the tumor. The immune TME may be modified to support the tumor and promote its progression while suppressing immune cell-mediated cytotoxicity. Substantial clinical and experimental evidence indicates that macrophages, abundant in most tumor types, play a major regulatory role in promoting tumor progression to malignancy. Both macrophages in primary tumors (tumor-associated macrophages or TAMs) and macrophages in metastatic tumors (metastasis-associated macrophages or MAMs) are abundant in most solid tumors and may be associated with tumor metastasis. The accumulation of TAMs, MAMs, and their progenitors appears to be driven by chemokine ligands released by tumor and stromal cells. For example, there is evidence that TAMs and MAMs are derived, at least in part, from CCR2-expressing monocytes recruited by CCL2-expressing tumor cells and / or CCL2-expressing stromal cells. However, the exact mechanisms are not fully defined, and other CCR2 ligands such as CCL12, cytokines such as VEGF and CSF1, and other chemoattractant signals such as CCL5-CCR5, CCL20-CCR6, CXCL12-CXCR4 may provide alternative or additional chemoattractant pathways for the recruitment of TAMs.Thus, efforts to target specific chemoattractant receptors or ligands, for example to specifically block the CCR2-CCL2 interaction, have not been completely effective, presumably because cancers can utilize alternative pathways.

[0003] Immune activation is primarily T-cell mediated and regulated by stimulatory, co-stimulatory and inhibitory (checkpoint) signals. When T cells encounter self cells, there are important receptor-ligand interactions that provide a check on activation so that the immune cells do not attack normal cells of the body. Cancer cells have genetic and epigenetic changes that can result in antigen expression that can induce immune activation, but they can also take advantage of these immune checkpoint interactions, such as PD-1 / PD-L1 and CTLA4 / B7-1 / B7-2, to inactivate immune cells and render the immune system ineffective against the destruction of the cancer. Immune checkpoint inhibitors have been effective in many patients suffering from various types of cancer, as they allow the destruction of the cancer by the patient's own immune system.

[0004] However, immunotherapy-related adverse events may limit the use of checkpoint inhibitor therapy and may cause severe adverse events. Inhibition of immune checkpoints allows the immune system to attack normal tissues. This leads to inflammatory conditions such as dermatitis, colitis, arthritis, nephritis, myositis, polymyalgia-like syndrome, and cytokine release syndrome (CRS), which is caused by the massive and rapid release of cytokines into the blood from immune cells affected by immunotherapy. These side effects can be very severe and sometimes fatal. Thus, immune checkpoint inhibition, despite being very beneficial for cancer patients, may be limited by the occurrence of immunotherapy-related adverse events.

[0005] Although 11 families of phosphodiesterases (PDEs) have been identified, only family I PDEs, Ca2+ / calmodulin-activated Ca2+ / calmodulin-dependent phosphodiesterases (CaM-PDEs), have been shown to mediate calcium-dependent cyclic nucleotide (e.g., cGMP and cAMP) signaling pathways. All three known CaM-PDE genes, PDE1A, PDE1B and PDE1C, are expressed in central nervous system tissues. PDE1A is expressed in the brain, lung and heart. PDE1B is expressed primarily in the central nervous system, but has also been detected in monocytes and neutrophils and has been shown to be involved in the inflammatory response of these cells. PDE1C is expressed in olfactory epithelium, cerebellar granule cells, striatum, heart and vascular smooth muscle. PDE1C has been demonstrated to be a major regulator of smooth muscle proliferation in human smooth muscle. Cyclic nucleotide phosphodiesterases downregulate intracellular cAMP and cGMP signaling by hydrolyzing these cyclic nucleotides to their respective 5' monophosphates (5'AMP and 5'GMP), which are inactive with respect to intracellular signaling pathways. Both cAMP and cGMP are central intracellular second messengers and play a role in regulating many cellular functions. PDE1A and PDE1B preferentially hydrolyze cGMP over cAMP, whereas PDE1C shows approximately equal cGMP and cAMP hydrolysis.

[0006] There is a substantial need for means to target multiple chemokine pathways involved in tumor recruitment of macrophages and other cells, as well as new therapies that complement and enhance checkpoint inhibitor therapy, as well as safe and selective strategies to mitigate the severe side effects (inflammatory-related adverse events) associated with checkpoint inhibitor therapy. Summary of the Invention

[0007] Disclosure Summary The inventors have previously shown that inhibition of PDE1 activity with the disclosed compounds can safely restore cAMP function in a wide range of pathological conditions, including models of neurodegeneration and neuroinflammation, heart failure, pulmonary hypertension and peripheral inflammation, as well as in humans with certain diseases. More recently, the inventors have shown that PDE1 inhibitors disrupt cell migration of microglia and monocytes. Recent evidence indicates that PDE1, particularly the PDE1C isoform, is overexpressed in experimental tumor models such as melanoma, neuroblastoma, renal cell carcinoma and colon cancer, as well as osteosarcoma. In addition, focal genomic over representation of PDE1C in glioblastoma multiforme (GBM) cells has been demonstrated. Genomic gain of PDE1C is associated with increased expression in GBM-derived cell cultures and is essential for promoting cell proliferation, migration and invasion of cancer cells.

[0008] Many types of cancer cells overexpress PDE1 activity, identified through various biomarkers such as increased RNA expression, DNA copy number, PDE1 binding (PET or radioisotope retention of PDE1 inhibitor molecules) or enzyme activity. These cancer cells also exhibit low levels of cAMP, which can be increased by PDE1 inhibitors. Such properties can be treated with PDE-1 inhibitors alone or in combination with chemotherapy, gene therapy and / or immunological approaches. Inhibiting PDE1 induces apoptotic cell death, prevents migration, limits metastasis and reduces inflammation. Thus, PDE1 inhibitors are synergistic with chemotherapy and immunological approaches.

[0009] Thus, the present disclosure provides PDE1 inhibitors for use in suppressing the recruitment of immune system cells, including macrophages and microglia, and other cells to cancer, and in suppressing the metastasis, tumor angiogenesis and growth, cancer cell invasion, and subversion of immune surveillance brought about by the recruited cells.PDE1 inhibits not only CCL2, but also other cytokines and chemokines thought to be involved in this recruitment, and is therefore expected to be more effective than therapies such as monoclonal antibodies or other specific inhibitors of CCR2-CCL2 interaction.

[0010] The present disclosure also provides the use of PDE1 inhibitors in combination with cancer immunotherapy, including checkpoint inhibitors, genome editing and CAR-T therapy, and these combinations should enhance the efficacy of these therapies by both reducing the interference with immune surveillance by TAM and MAM, and reducing inflammatory-related adverse events associated with checkpoint inhibitor therapy, such as cytokine release syndrome (CRS).PDE1 inhibition is prophylactically and therapeutically useful in these cases, and PDE1 inhibitors can be administered with other anti-inflammatory agents, such as corticosteroids and antihistamines, to prevent CRS and other inflammatory conditions resulting from checkpoint inhibitor therapy.

[0011] The combination of PDE1 inhibitor therapy, known to be anti-inflammatory, with immunostimulatory checkpoint inhibitor therapy may seem counterintuitive, but nevertheless, the dual effects of PDE1 inhibitors may be effective in (i) inhibiting cancer-induced recruitment of protective cells, particularly macrophages, and (ii) reducing the risk of cytokine release syndrome and other side effects of checkpoint inhibitor therapy.

[0012] The present disclosure also provides the use of PDE1 inhibitors for the treatment of cancer or tumor, including, for example, carcinoma, melanoma and astrocytoma.Furthermore, the reduction of cAMP (or cGMP) level can result from the overexpression of PDE1 isoforms in various cancer pathologies.The inhibition of selective PDE1 isoforms, which increases the level of intracellular cAMP (and / or cGMP), induces apoptosis and cell cycle arrest in a wide range of tumor cells, and regulates the tumor microenvironment, which prevents cell migration, inflammation and tissue invasion.Therefore, the development and clinical application of specific inhibitors for individual PDE1 can selectively restore normal intracellular signaling and provide antitumor therapy with reduced adverse effects.

[0013] Previous studies have shown that PDE1 (i.e., PDE1C) is significantly overexpressed in the tumor environment of glioblastoma patients compared to healthy patients (i.e., patients without glioblastoma). siRNA-mediated silencing of PDE1C has been shown to inhibit proliferation and invasion in glioblastoma patient-derived cell cultures. Without being bound by any theory, inhibition of PDE1 may be effective in the therapeutic intervention of certain cancers or tumors, such as glioblastoma. In particular, the treatment of brain tumors requires compounds that have the ability to cross the blood-brain barrier. The compounds of the present disclosure are potent inhibitors of PDE1. In particular, the compounds of the present disclosure show high selectivity for PDE1 and can cross the blood-brain barrier.

[0014] Thus, in various embodiments, the present disclosure provides a method for treating a condition selected from cancer or tumor, comprising administering to a subject in need of said treatment a pharmacologic acceptable amount of PDE1 inhibitor as disclosed herein.In some embodiments, cancer or tumor is glioma, leukemia, lymphoma, melanoma, neuroblastoma, carcinoma or osteosarcoma.In some embodiments, cancer or tumor is astrocytoma, such as glioblastoma multiforme.In some embodiments, PDE1 inhibitor is administered in combination with antitumor agent.

[0015] In various embodiments, the present disclosure provides a method for inhibiting the proliferation, migration and / or invasion of neoplastic cells, comprising administering a pharma- ceutically acceptable amount of a PDE1 inhibitor as disclosed herein to a subject in need of such inhibition.In some embodiments, the cancer or tumor is glioma, leukemia, melanoma, neuroblastoma, carcinoma or osteosarcoma.In some embodiments, the cancer or tumor is astrocytoma, such as glioblastoma multiforme.In some embodiments, the PDE1 inhibitor is administered in combination with an antitumor agent.

[0016] In various embodiments, the present application provides a method for treating glioma, comprising administering a pharmacologic acceptable amount of PDE1 inhibitor to a subject in need of such treatment.In some embodiments, cancer or tumor is astrocytoma, such as glioblastoma multiforme.In some embodiments, PDE1 inhibitor is administered in combination with antitumor agent.

[0017] In another aspect, the present disclosure also includes the PDE1 inhibitors shown in the following formula I, Ia, II, III, IV, V and / or VI in free form or salt form.In a preferred embodiment, the PDE1 inhibitor is a selective PDE1 inhibitor.In another embodiment, the disclosure further provides a pharmaceutical composition comprising the PDE1 inhibitor in free form or pharma-ceutically acceptable salt form mixed with a pharma-ceutically acceptable carrier.

[0018] In various embodiments, the present disclosure provides a combination therapy comprising the PDE1 inhibitor of the following formula I, Ia, II, III, IV, V and / or VI in free or salt form and an antitumor agent.The combination therapy can be used in conjunction with any of the methods disclosed herein.In some embodiments, the antitumor agent is administered concurrently, before or after the administration of the PDE1 inhibitor.

[0019] In various embodiments, the present disclosure also provides pharmaceutical compositions comprising the compounds of the present disclosure, prepared using conventional diluents or excipients and techniques known in the art. Thus, oral dosage forms can include tablets, capsules, solutions, suspensions, and the like.

[0020] In various embodiments, the disclosure also provides PDE1 inhibitors according to formula I, Ia, II, III, IV, V and / or VI below, in free or salt form, for use in treating a condition selected from cancer or tumor, inhibiting neoplastic cell proliferation, migration and / or invasion, or treating glioma. [Brief description of the drawings]

[0021] [Figure 1] Figure 1 shows phosphodiesterase expression in BV2 cells treated with LPS-RNAseq analysis. FPKM refers to Fragment Reads per kilobase of exon per million reads mapped.

[0022] [Diagram 2] FIG. 2 shows that a PDE1 inhibitor (compound 214) suppresses LPS-induced IL1β in BV2 cells.

[0023] [Diagram 3] Figure 3a shows that a PDE1 inhibitor (compound 214) significantly reduces LPS-induced increases in the expression of inflammatory cytokines IL1β, TNFα and Ccl2 in BV2 cells as measured by quantitative PCR, whereas the PDE4 inhibitor rolipram shows a different profile. In a separate experiment, Figure 3b shows that administration of a PDE1 inhibitor of the present invention (compound 214) significantly reduces or blunts LPS-induced changes in proinflammatory markers in BV2 cells (Figure 3b).

[0024] [Figure 4] FIG. 4 shows inhibition of LPS-induced TNFα release from BV2 cells.

[0025] [Diagram 5] FIG. 5 shows a dose-dependent reduction of LPS-stimulated TNFα mRNA expression by PDE1 inhibitors.

[0026] [Figure 6] Figure 6 shows that a PDE1 inhibitor (compound 214) prevents LPS-induced inflammatory gene expression changes in mice. Adult mice are treated with vehicle (white bars), LPS 500 μg / kg sc (gray bars), or ITI-214 10 mg / kg ip and LPS 500 μg / kg sc (black bars) for 2 hours (n=4). Striatal tissue is analyzed for TNF, IL1β, Ccl2 and IL6 mRNA levels. Expression levels are shown as change from Q-PCR signal change from vehicle (□□Ct) and compared using ANOVA. *p<0.05, **p<0.01, ***p<0.001.

[0027] [Figure 7] Figure 7 generally shows how compound 214 inhibits ADP-induced chemotaxis in BV2 cells by enhancing cAMP and P-VASP (S157) levels. Figure 7A shows chemotaxis to 100M ADP measured for 4 hours in a Boyden chamber system. Figure 7B shows dose-dependent inhibition of ADP chemotaxis by P2RY12 inhibitors.

[0028] [Figure 8]FIG. 8 shows the chemotactic effect in BV2 cells treated with ITI-214 or IBMX for 30 min before stimulating with ADP for 5 min; the resulting phosphorylated VASP at S157 and the resulting band intensities measured; and the total VASP levels of the samples tested. FIG. 8A shows cyclic AMP levels normalized to vehicle values ​​in pmol cAMP / cell number. FIG. 8B shows the levels of phosphorylation of VASP at serine 157 measured by Western blot. The top graph shows phosphorylation and the bottom graph shows the levels of total VASP. The inset shows a representative sample; the same samples were loaded on each blot in the order shown in the bar graph. The green bands are p-VASP (top) or total VASP (bottom). Samples were normalized to actin (red band) as a loading control.

[0029] [Figure 9] FIG. 9 shows the dose-dependent nature of the resulting increase in cAMP following exposure to Compound 214.

[0030] [Figure 10] FIG. 10 shows ADP-induced p-VASP(S157) levels in cultured primary rat microglia after treatment with compound 214.

[0031] [Figure 11] FIG. 11 shows the effect of anti-PD-1 and compound 214, both alone and in combination, on tumor size in mice injected with CT26 colorectal cancer cells.

[0032] [Figure 12] FIG. 12 shows the effect of anti-PD-1 and compound 214, both alone and in combination, on CD45-positive macrophage infiltration in mice injected with CT26 colorectal cancer cells. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0033] Detailed Description of the Invention Compounds for use in the disclosed methods

[0034] In one embodiment, the PDE1 inhibitors for use in the methods of treatment and prevention described herein are selective PDE1 inhibitors.

[0035] PDE1 Inhibitors

[0036] In one embodiment, the present invention provides that the PDE1 inhibitor for use in the methods of treatment and prevention described herein is a compound of formula I: [ka] [In the formula, (i) R1 is H or C 1-4 alkyl (e.g., methyl); (ii) R4 is H or C 1-4 alkyl, and R and R are independently H or C 1-4 alkyl (e.g., R2 and R3 are both methyl, or R2 is H and R3 is isopropyl), aryl, heteroaryl, (optionally hetero)arylalkoxy, or (optionally hetero)arylalkyl; or R2 is H, and R3 and R4 together form a dimethylene, trimethylene or tetramethylene bridge (preferably, R3 and R4 together have a cis configuration, e.g., the carbons bearing R3 and R4 have the R and S configurations, respectively); (iii) R5 is a substituted heteroarylalkyl, e.g., substituted with haloalkyl; or R5 is attached to one of the nitrogens of the pyrazolo moiety of formula I and has formula A: [ka] (Wherein, X, Y and Z are independently N or C; R8, R9, R 11 and R 12 are independently H or halogen (e.g., Cl or F), and R 10 is halogen, alkyl, cycloalkyl, haloalkyl (e.g., trifluoromethyl), aryl (e.g., phenyl), heteroaryl (e.g., pyridyl (e.g., pyrid-2-yl), or thiadiazolyl (e.g., 1,2,3-thiadiazol-4-yl) optionally substituted with halogen), diazolyl, triazolyl, tetrazolyl, arylcarbonyl (e.g., benzoyl), alkylsulfonyl (e.g., methylsulfonyl), heteroarylcarbonyl, or alkoxycarbonyl; provided that when X, Y, or Z is nitrogen, then R, R, or R, respectively, are each independently selected from the group consisting of aryl, aryl, aryl, and alkyl. 10 does not exist) The part indicated by; (iv) R6 is H, alkyl, aryl, heteroaryl, arylalkyl (e.g., benzyl), arylamino (e.g., phenylamino), heteroarylamino, N,N-dialkylamino, N,N-diarylamino, or N-aryl-N-(arylalkyl)amino (e.g., N-phenyl-N-(1,1'-biphen-4-ylmethyl)amino); (v) n is 0 or 1; (vi) When n is 1, A is -C(R 13 R 14 )-(where R 13 and R 14 are independently H or C 1-4 alkyl, aryl, heteroaryl, (optionally hetero)arylalkoxy or (optionally hetero)arylalkyl)]. The compound is represented by the formula:

[0037] In another embodiment, the present invention provides that the PDE1 inhibitor for use in the methods described herein is a compound represented by formula 1a: [ka] [In the formula, (i) R2 and R5 are independently H or hydroxy and R3 and R4 together form a trimethylene or tetramethylene bridge [preferably the carbons bearing R3 and R4 have the R and S configurations, respectively]; or R2 and R3 are each methyl and R4 and R5 are each H; or R2, R4 and R5 are H and R3 is isopropyl [preferably the carbon bearing R3 has the R configuration]; (ii) R6 is phenylamino (optionally halo-substituted), benzylamino (optionally halo-substituted), C 1-4 Alkyl, or C 1-4 alkylsulfide; for example, phenylamino or 4-fluorophenylamino; (iii) R 10 is C 1-4 alkyl, methylcarbonyl, hydroxyethyl, carboxylic acid, sulfonamide, (optionally halo- or hydroxy-substituted) phenyl, (optionally halo- or hydroxy-substituted) pyridyl (e.g., 6-fluoropyrid-2-yl), or thiadiazolyl (e.g., 1,2,3-thiadiazol-4-yl); (iv) X and Y are independently C or N. Provide that.

[0038] In another embodiment, the present invention provides a PDE1 inhibitor for use in the methods of treatment and prevention described herein, comprising a compound of formula II: [ka] [In the formula, (i) X is C 1-6 alkylene (e.g., methylene, ethylene or prop-2-yn-1-ylene); (ii) Y is a single bond, alkynylene (e.g., -C≡C-), arylene (e.g., phenylene) or heteroarylene (e.g., pyridylene); (iii) Z is H, aryl (e.g., phenyl), heteroaryl (e.g., pyridyl, e.g., pyrid-2-yl), halo (e.g., F, Br, Cl), haloC 1-6 Alkyl (e.g., trifluoromethyl), -C(O)-R 1 , -N(R 2 )(R 3 ), or C, which may contain at least one atom selected from the group consisting of N or O. 3-7 cycloalkyl (e.g., cyclopentyl, cyclohexyl, tetrahydro-2H-pyran-4-yl, or morpholinyl); (iv) R 1 is C 1-6 Alkyl, haloC 1-6 Alkyl, -OH or -OC 1-6 alkyl (e.g., -OCH3); (v) R 2 and R 3 are independently H or C 1-6 is alkyl; (vi) R 4 and R 5 are independently H, C 1-6 Alkyl, or one or more halo (e.g., fluorophenyl, e.g., 4-fluorophenyl), hydroxy (e.g., hydroxyphenyl, e.g., 4-hydroxyphenyl or 2-hydroxyphenyl) or C 1-6 aryl (e.g., phenyl) optionally substituted with alkoxy; (vii) where X, Y and Z are independently one or more halo (e.g., F, Cl or Br), C 1-6 Alkyl (e.g., methyl), haloC 1-6For example, Z may be substituted with one or more halo (e.g., 6-fluoropyrid-2-yl, 5-fluoropyrid-2-yl, 6-fluoropyrid-2-yl, 3-fluoropyrid-2-yl, 4-fluoropyrid-2-yl, 4,6-dichloropyrid-2-yl), haloC 1-6 Alkyl (e.g., 5-trifluoromethylpyrid-2-yl) or C 1-6 -heteroaryl, e.g., pyridyl, substituted with alkyl (e.g., 5-methylpyrid-2-yl); or Z is aryl, e.g., phenyl, substituted with one or more halo (e.g., 4-fluorophenyl). The compound is represented by the formula:

[0039] In yet another embodiment, the present invention provides a PDE1 inhibitor for use in the methods of treatment and prevention described herein, comprising a compound of formula III: [ka] [In the formula, (i) R1 is H or C 1-4 alkyl (e.g., methyl or ethyl); (ii) R2 and R3 are independently H or C 1-6 alkyl (e.g., methyl or ethyl); (iii) R4 is H or C 1-4 alkyl (e.g., methyl or ethyl); (iv) R5 is independently -C(=O)-C 1-6 Alkyl (e.g., -C(=O)-CH3) and C 1-6 -aryl (e.g., phenyl) optionally substituted with one or more groups selected from hydroxyalkyl (e.g., 1-hydroxyethyl); (v) R6 and R7 are independently H or independently C 1-6Aryl (e.g., phenyl) optionally substituted with one or more groups selected from alkyl (e.g., methyl or ethyl) and halogen (e.g., F or Cl), e.g., unsubstituted phenyl, or phenyl substituted with one or more halogen (e.g., F), or one or more C 1-6 Phenyl substituted with alkyl and one or more halogens, or one C 1-6 phenyl substituted with alkyl and one halogen, such as 4-fluorophenyl or 3,4-difluorophenyl or 4-fluoro-3-methylphenyl; (vi) n is 1, 2, 3 or 4. Provide that.

[0040] In yet another embodiment, the present invention provides a PDE1 inhibitor for use in the methods of treatment and prevention described herein, comprising a compound of formula IV: [ka] [In the formula, (i) R1 is C 1-4 alkyl (e.g., methyl or ethyl), or -NH(R2), where R2 is phenyl optionally substituted with halo (e.g., fluoro), such as 4-fluorophenyl; (ii) X, Y and Z are independently N or C; (iii) R3, R4 and R5 are independently H or C 1-4 alkyl (e.g., methyl); or R3 is H and R4 and R5 together form a trimethylene bridge (preferably, R4 and R5 together have a cis configuration, e.g., the carbons carrying R4 and R5 have the R and S configurations, respectively); (iv) R6, R7 and R8 are independently H, C 1-4 Alkyl (e.g., methyl), hydroxy-substituted pyrid-2-yl; or -S(O)2-NH2 and; (v) with the proviso that when X, Y and / or Z are N, R6, R7 and / or R8 are absent, respectively; and when X, Y and Z are all C, at least one of R6, R7 or R8 is -S(O)2-NH2, or pyrid-2-yl substituted with hydroxy. Provide that.

[0041] In another embodiment, the present invention provides a PDE1 inhibitor for use in the methods as described herein, comprising a compound of formula V: [ka] [In the formula, (i) R1 is -NH(R4), where R4 is phenyl optionally substituted with halo (e.g., fluoro), such as 4-fluorophenyl; (ii) R2 is H or C 1-6 alkyl (e.g., methyl, isobutyl, or neopentyl); (iii) R3 is -SO2NH2 or -COOH. Provide that.

[0042] In another embodiment, the present invention provides a PDE1 inhibitor for use in the methods as described herein, comprising a compound of formula VI: [ka] [In the formula, (i) R1 is -NH(R4), where R4 is phenyl optionally substituted with halo (e.g., fluoro), such as 4-fluorophenyl; (ii) R2 is H or C 1-6 alkyl (e.g., methyl or ethyl); (iii) R3 is H, halogen (e.g., bromo), C 1-6alkyl (e.g., methyl), aryl optionally substituted with halogen (e.g., 4-fluorophenyl), heteroaryl optionally substituted with halogen (e.g., 6-fluoropyrid-2-yl or pyrid-2-yl), or acyl (e.g., acetyl). Provide that.

[0043] In one embodiment, the disclosure relates to the administration of a PDE1 inhibitor (e.g., a compound of Formula I, Ia, II, III, IV, V and / or VI) for use in the methods described herein, wherein the inhibitor is [ka] [ka] [ka] [ka] The present invention provides a compound represented by the formula:

[0044] In one embodiment, the present invention relates to the administration of a PDE1 inhibitor for treatment or prevention as described herein, wherein the inhibitor is one of the following, in free form or in pharma- ceutically acceptable salt form: [ka] The present invention provides a compound represented by the formula:

[0045] In yet another embodiment, the present invention relates to the administration of a PDE1 inhibitor for treatment or prevention as described herein, wherein the inhibitor is one of the following, in free form or in pharma- ceutically acceptable salt form: [ka] The present invention provides a compound represented by the formula:

[0046] In yet another embodiment, the present invention relates to the administration of a PDE1 inhibitor for treatment or prevention as described herein, wherein the inhibitor is one of the following, in free form or in pharma- ceutically acceptable salt form: [ka] The present invention provides a compound represented by the formula:

[0047] In yet another embodiment, the present invention relates to the administration of a PDE1 inhibitor for treatment or prevention as described herein, wherein the inhibitor is one of the following, in free form or in pharma- ceutically acceptable salt form: [ka] The present invention provides a compound represented by the formula:

[0048] In one embodiment, a selective PDE1 inhibitor according to any of the above formulas (e.g., Formula I, Ia, II, III, IV, V and / or VI) is a compound that inhibits phosphodiesterase-mediated (e.g., PDE1-mediated, particularly PDE1B-mediated) hydrolysis of cGMP, e.g., preferred compounds have an IC of less than 1 μM, preferably less than 500 nM, preferably less than 50 nM, preferably less than 5 nM, in the immobilized metal affinity particle reagent PDE assay, in free or salt form. 50 has.

[0049] In another embodiment, the present invention provides the administration of a PDE1 inhibitor for the treatment of a condition selected from cancer or tumor; for the inhibition of neoplastic cell proliferation, migration and / or invasion; and / or for the treatment of glioma, wherein the inhibitor is selected from the group consisting of the following, in free form or in pharma- ceutical acceptable salt form: [ka] The present invention provides a compound represented by the formula:

[0050] Further examples of PDE1 inhibitors suitable for use in the methods and treatments described herein are described in WO 2006133261 (A2); U.S. Patent No. 8,273,750; U.S. Patent No. 9,000,001; U.S. Patent No. 9,624,230; WO 2009075784 (A1); U.S. Patent No. 8,273,751; U.S. Patent No. 8,829,008; U.S. Patent No. 9,403,836; No. 2014151409 (A1), U.S. Pat. No. 9,073,936; U.S. Pat. No. 9,598,426; U.S. Pat. No. 9,556,186; U.S. Patent Application Publication No. 2017 / 0231994 (A1), WO 2016022893 (A1), and U.S. Patent Application Publication No. 2017 / 0226117 (A1), each of which is incorporated herein by reference in its entirety.

[0051] Still further examples of PDE1 inhibitors suitable for use in the methods and treatments described herein include those described in WO 2018007249 (A1); U.S. Patent Application Publication No. 2018 / 0000786; WO 2015118097 (A1); U.S. Patent No. 9,718,832; WO 2015091805 (A1); U.S. Patent No. 9,701,665; U.S. Patent Application Publication No. 2015 / 0175584 (A1); U.S. Patent Application Publication No. 2017 / 0267664 (A1); WO No. 2016055618 (A1); U.S. Patent Application Publication No. 2017 / 0298072 (A1); International Publication No. 2016170064 (A1); U.S. Patent Application Publication No. 2016 / 0311831 (A1); International Publication No. 2015150254 (A1); U.S. Patent Application Publication No. 2017 / 0022186 (A1); International Publication No. 2016174188 (A1); U.S. Patent Application Publication No. 2016 / 0318939 (A1); U.S. Patent Application Publication No. 2017 / 0291903 (A1); International Publication No. 20180 73251 (A1); WO 2017178350 (A1); U.S. Patent Application Publication No. 2017 / 0291901 (A1); WO 2018 / 115067; U.S. Patent Application Publication No. 2018 / 0179200 (A); U.S. Patent Application Publication No. 20160318910 (A1); U.S. Patent No. 9,868,741; WO 2017 / 139186 (A1); WO 2016 / 040083; U.S. Patent Application Publication No. 2017 / 0240532; WO 2016033776 ( A1); U.S. Patent Application Publication No. 2017 / 0233373; International Publication No. 2015130568; International Publication No. 2014159012; U.S. Patent No. 9,034,864; U.S. Patent No. 9,266,859; International Publication No. 2009085917; U.S. Patent No. 8,084,261; International Publication No. 2018039052; U.S. Patent Application Publication No. 20180062729; and International Publication No. 2019027783 (each of which is incorporated herein by reference in its entirety). In the event that the statements in the documents incorporated herein by reference conflict or are incompatible with the statements in this disclosure, the statements in this disclosure shall be understood to control.

[0052] The disclosed methods of treatment with PDE1 inhibitors are further disclosed in U.S. Provisional Application No. 62 / 676,638, filed May 25, 2018, and U.S. Provisional Application No. 62 / 688,641, filed June 22, 2018, both of which are incorporated herein by reference in their entireties; and WO 2018049417(A1), which is incorporated herein by reference.

[0053] Unless otherwise specified or clear from context, the following terms used herein have the following meanings:

[0054] a. "Selective PDE1 inhibitor," as used herein, refers to a PDE1 inhibitor whose inhibition of PDE1 is at least 100-fold more selective than inhibition of any other PDE isoform.

[0055] b. "Alkyl," as used herein, means a saturated or unsaturated hydrocarbon moiety, preferably saturated, preferably having 1 to 6 carbon atoms, which may be straight or branched, and which may be mono-, di-, or tri-substituted, for example, with halogen (e.g., chloro or fluoro), hydroxy, or carboxy.

[0056] c. "Cycloalkyl" as used herein means a saturated or unsaturated non-aromatic hydrocarbon moiety, preferably saturated, containing preferably 3 to 9 carbon atoms, at least some of which form a non-aromatic monocyclic or bicyclic or bridged ring structure, optionally substituted, for example, with halogen (e.g., chloro or fluoro), hydroxy or carboxy. When the cycloalkyl optionally contains one or more atoms selected from N and O and / or S, the cycloalkyl may be a heterocycloalkyl.

[0057] d. "Heterocycloalkyl" means, unless otherwise specified, a saturated or unsaturated non-aromatic hydrocarbon moiety, preferably saturated, containing preferably from 3 to 9 carbon atoms, at least some of which are formed into a non-aromatic monocyclic or bicyclic or bridged ring structure, in which at least one carbon atom is replaced by N, O or S, and in which the heterocycloalkyl is optionally substituted, for example, by halogen (e.g., chloro or fluoro), hydroxy or carboxy.

[0058] e. "Aryl," as used herein, refers to a monocyclic or bicyclic aromatic hydrocarbon, preferably phenyl, optionally substituted with, for example, alkyl (e.g., methyl), halogen (e.g., chloro or fluoro), haloalkyl (e.g., trifluoromethyl), hydroxy, carboxy, or further aryl or heteroaryl (e.g., biphenyl or pyridylphenyl).

[0059] f. "Heteroaryl," as used herein, refers to an aromatic moiety in which one or more of the atoms in the aromatic ring is sulfur or nitrogen rather than carbon, e.g., pyridyl or thiadiazolyl, and may be optionally substituted, e.g., with alkyl, halogen, haloalkyl, hydroxy or carboxy.

[0060] The disclosed compounds, for example, PDE1 inhibitors as described herein, can be in free form or salt form, for example, as acid addition salt.In this specification, unless otherwise specified, the phrase "disclosed compounds" and the like should be understood to include the compounds in any form, for example, in free form or acid addition salt form, or in base addition salt form if the compounds contain acidic substituents.Since the disclosed compounds are intended to be used as pharmaceuticals, pharma-ceutically acceptable salts are preferred.Salts that are not suitable for pharmaceutical use may be useful, for example, for the isolation or purification of the disclosed compounds in free form or their pharma-ceutically acceptable salts, and therefore also include such salts.

[0061] The disclosed compounds may also exist in prodrug form in some cases. Prodrug form is a compound that is converted to the disclosed compounds in the body. For example, when the disclosed compounds contain hydroxy or carboxy substituents, these substituents can form physiologically hydrolyzable and acceptable esters. As used herein, "physiologically hydrolyzable and acceptable esters" refers to esters of the disclosed compounds that are hydrolyzable under physiological conditions and produce physiologically acceptable acids (in the case of the disclosed compounds with hydroxy substituents) or alcohols (in the case of the disclosed compounds with carboxy substituents) at the doses to be administered. Thus, when the disclosed compounds contain hydroxy groups, such as compound-OH, the acyl ester prodrugs of the compounds, i.e., compound-OC(O)-C1-4 alkyl, can be hydrolyzed in the body to form physiologically hydrolyzable alcohols (compound-OH) on the one hand, and acids (e.g., HOC(O)-C1-4 alkyl) on the other hand. Alternatively, when a compound of the present disclosure contains a carboxylic acid, for example Compound-C(O)OH, the acid ester prodrug of the compound, Compound-C(O)O-C1-4 alkyl, can be hydrolyzed to form Compound-C(O)OH and HO-C1-4 alkyl. Thus, as will be understood, the term encompasses conventional pharmaceutical prodrug forms.

[0062] In another embodiment, the present disclosure further provides a pharmaceutical composition comprising a PDE1 inhibitor in combination with an antitumor agent, each in free form or in pharma- ceutically acceptable salt form, mixed with a pharma- ceutically acceptable carrier.The term "combination" as used herein includes simultaneous, sequential, or contemporaneous administration of a PDE1 inhibitor and an antitumor agent.In another embodiment, the present disclosure provides a pharmaceutical composition containing such a compound.In some embodiments, the combination of a PDE1 inhibitor and an antitumor agent allows the antitumor agent to be administered in a lower amount than would be effective if administered as a single monotherapy.

[0063] Methods of Using the Disclosed Compounds

[0064] In one embodiment, the present application provides a method for producing a composition comprising: a. Cancer or tumor recruitment of immune cells, such as macrophages (e.g., TAMs or MAMs) and / or microglia, e.g., chemokine-mediated recruitment, e.g., CCL2-mediated recruitment; b. Tumor or cancer metastasis, e.g., TAM-associated or MAM-associated metastasis; c. Tumor or cancer angiogenesis, e.g., TAM-associated or MAM-associated angiogenesis; d. Disruption of tumor or cancer immune surveillance, e.g., disruption of TAM-associated or MAM-associated immune surveillance. The present invention provides a method for treating cancer or tumors by inhibiting PDE1, comprising administering to a subject in need of such treatment a pharma- ceutically acceptable amount of a PDE1 inhibitor (e.g., a PDE1 inhibitor represented by Formula I, Ia, II, III, IV, V and / or VI), optionally in conjunction with or in association with a checkpoint inhibitor (Method 1).

[0065] 1.1 Method 1, wherein the cancer or tumor has increased expression of PDE1.

[0066] 1.2 Any of the above methods, wherein said method comprises inhibiting tumor recruitment of immune cells.

[0067] 1.3 Any of the above methods, wherein said method comprises inhibiting tumor recruitment of macrophages and / or microglia.

[0068] 1.4 Any of the above methods, wherein said method comprises a method of inhibiting tumor recruitment of macrophages and / or microglia, said recruitment being mediated, at least in part, by increased expression of CCL2 by tumor cells and / or cells within the tumor microenvironment.

[0069] 1.5 Any of the above methods, wherein said method comprises a method of inhibiting tumor metastasis.

[0070] 1.6 Any of the above methods, wherein said method comprises a method of inhibiting tumor angiogenesis.

[0071] 1.7 Any of the above methods, wherein said method comprises inhibiting the subversion of tumor immune surveillance.

[0072] 1.8 Any of the above methods, wherein the cancer or tumor cells exhibit one or more of increased PDE1 RNA expression, DNA copy number, PDE1 binding (e.g., PET or radioisotope loading of PDE1 inhibitor molecules), modifications to the PDE1 enzyme (i.e., cleavage of the receptor causing loss of calcium / calmodulin control), or PDE1 enzyme activity (e.g., as measured by an enzyme assay or reflected by lower levels of cAMP in the cancer cells or in intracellular domains of the cancer cells, e.g., microtubule domains) compared to normal cells of the same tissue type as the cancer cells.

[0073] 1.9 Any of the above methods, wherein the subject has a tumor.

[0074] 1.10 The subject is diagnosed with an acoustic neuroma, astrocytoma, chordoma, lymphoma (e.g., CNS lymphoma, Hodgkin's lymphoma, or non-Hodgkin's lymphoma), craniopharyngioma, glioma (e.g., brain stem glioma, ependymoma, mixed glioma, optic nerve glioma), subependymoma, medulloblastoma, meningioma, metastatic brain tumor, oligodendroglioma, pituitary tumor, primitive neuroectodermal tumor (PNET), Schwannoma, adenoma (e.g., basophilic adenoma, acidophilic adenoma, chromophobe adenoma, parathyroid adenoma, pancreatic islet adenoma, fibroadenoma), fibroid (fibrous histiocytoma), fibroma, hemangioma, lipoma (e.g., angiolipoma, myelolipoma, fibrolipoma, spindle cell lipoma, brown lipoma, atypical lipoma), Myxoma, osteoma, preleukemia, rhadomyoma, papilloma, seborrheic keratosis, skin adnexal tumor, hepatic adenoma, renal tubular adenoma, bile duct adenoma, transitional cell papilloma, hydatidiform mole, ganglioneuroma, meningioma, schwannoma, neurofibroma, C-cell hyperplasia, pheochromocytoma, insulinoma, gastrinoma, carcinoid, chemodectoma, paraganglioma, nevus, actinic keratosis, cervical dysplasia, metaplasia (e.g., pulmonary metaplasia), leukoplakia, hemangioma, lymphangioma, carcinoma (e.g., squamous cell carcinoma, epidermoid carcinoma, adenocarcinoma, hepatoma, hepatocellular carcinoma, renal cell carcinoma, cholangiocarcinoma, transitional cell carcinoma, embryonal cell carcinoma, cell carcinoma, parathyroid carcinoma, medullary thyroid carcinoma, bronchial carcinoid, oat cell carcinoma, islet cell carcinoma, malignant carcinoid, Merkel cell tumor, colon carcinoma), sarcomas (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, malignant fibrous histiocytoma, hemangiosarcoma, angiosarcoma, lymphangiosarcoma, leiomyosarcoma, rhabdomyosarcoma, neurofibrosarcoma), blastomas (e.g., medulloblastoma and glioblastoma, types of brain tumors) tumor, retinoblastoma, tumor of the retina of the eye, osteoblastoma, bone tumor, neuroblastoma, germ cell tumor, mesothelioma, malignant skin adnexal tumor, hypernephroma, seminoma, glioma, malignant meningioma, malignant schwannoma, malignant pheochromocytoma, malignant paraganglioma, melanoma, merkel cell neoplasm, cystosarcoma phyllodesAny of the above methods, wherein the patient has a tumor or cancer selected from one or more of: Mycobacterium tuberculosis, Mycobacterium tuberculosis (Mycobacterium tuberculosis), ..., Mycobacterium tuberculosis, Mycobacterium tube

[0075] 1.11 Any of the above methods, wherein the subject has a glioma, osteosarcoma, melanoma, leukemia, lymphoma, carcinoma, or neuroblastoma.

[0076] 1.12 Any of the above methods, wherein the subject has a glioma (e.g., ependymoma, astrocytoma, oligodendroglioma, brain stem glioma, optic nerve glioma, or mixed glioma, e.g., oligoastrocytoma).

[0077] 1.13 Any of the above methods, wherein the subject has an astrocytoma (e.g., glioblastoma multiforme).

[0078] 1.14 Any of the above methods, wherein the subject has glioblastoma multiforme.

[0079] 1.15 Any of the above methods, wherein the subject has lymphoma.

[0080] 1.16 Any of the above methods, wherein the subject has lung cancer, pancreatic cancer, prostate cancer, urothelial cancer, head and neck cancer, or leukemia.

[0081] 1.17 Any of the above methods, wherein the subject has lymphocytic or myeloid leukemia.

[0082] 1.18 Any of the above methods, wherein the subject has cancer of the kidney, ureter, bladder, or urethra.

[0083] 1.19 Any of the above methods comprising administration of a PDE1 inhibitor to a patient receiving or who will be receiving an immune checkpoint inhibitor, e.g., an inhibitor of CTLA-4, PD-1 and / or PD-L1.

[0084] 1.20 Any of the above methods comprising administration of a PDE1 inhibitor to a patient receiving or who will be receiving an immune checkpoint inhibitor selected from one or more members selected from: nivolumab, pembrolizumab, cemiplimab, ipilimumab, avelumab, durvalumab, atezolizumab, spartalizumab.

[0085] 1.21 Any of the above methods comprising administration of a PDE1 inhibitor to a patient receiving or who will be receiving an inhibitor of CTLA-4.

[0086] 1.22 Any of the above methods comprising administration of a PDE1 inhibitor to a patient receiving or who will receive an inhibitor of PD-1.

[0087] 1.23 Any of the above methods comprising administration of a PDE1 inhibitor to a patient receiving or who will receive an inhibitor of PD-L1.

[0088] 1.24 Any of the above methods, wherein the immune checkpoint inhibitor is administered simultaneously with the PDE1 inhibitor.

[0089] 1.25 Any of the above methods, wherein the immune checkpoint inhibitor is administered prior to administration of the PDE1 inhibitor.

[0090] 1.26 Any of the above methods, wherein the immune checkpoint inhibitor is administered following administration of the PDE1 inhibitor.

[0091] 1.27 Any of the above methods, wherein the subject in need of said treatment has prior or concomitantly been administered checkpoint inhibitor therapy.

[0092] 1.28 Any of the above methods, wherein the subject in need of said treatment is suffering from a disease, disorder, or adverse effects of immune checkpoint inhibitor therapy.

[0093] 1.29 Any of the above methods, wherein the subject is suffering from an inflammation-associated disorder as a result of immune checkpoint inhibitor therapy.

[0094] 1.30 Any of the above methods, wherein the subject is suffering from or at risk of suffering from a side effect of immune checkpoint inhibitor therapy, e.g., the side effect is selected from a systemic inflammatory response, a gastroenteritis-related disorder, an endocrine inflammation-related disorder, a dermatological inflammation-related disorder, an ophthalmological inflammation-related disorder, a neurological inflammation-related disorder, a hematological inflammation-related disorder, a genitourinary inflammation-related disorder, a respiratory inflammation-related disorder, a musculoskeletal inflammation-related disorder, a cardiac inflammation-related disorder, or a defined systemic inflammation-related disorder.

[0095] 1.31 Any of the above methods, wherein the subject is suffering from a side effect of immune checkpoint inhibitor therapy, wherein the side effect is a gastroenteritis-related disorder, e.g., selected from colitis, enterocolitis, colitis complicated by intestinal perforation, hepatitis, and pancreatitis.

[0096] 1.32 Any of the above methods, wherein the subject is suffering from a side effect of immune checkpoint inhibitor therapy, wherein the side effect is an endocrine inflammation-related disorder selected from, e.g., hypophysitis (e.g., presenting with panhypopituitarism), thyrotoxicosis, hypothyroidism, syndrome of inappropriate secretion of antidiuretic hormone, central adrenal insufficiency, primary adrenal insufficiency, and diabetes mellitus.

[0097] 1.33 Any of the above methods, wherein the subject is suffering from a side effect of immune checkpoint inhibitor therapy, wherein the side effect is a dermatological inflammation-related disorder selected from, e.g., rash, pruritus, vitiligo vulgaris, dermatitis, Sweet's syndrome, drug rash, gray hair, delayed hypersensitivity reaction, alopecia universalis, Grover's disease, pyoderma gangrenosum, toxic epidermal necrolysis, chronic noncaseating granuloma, bullous pemphigoid, and psoriasis.

[0098] 1.34 Any of the above methods, wherein the subject is suffering from a side effect of immune checkpoint inhibitor therapy, wherein the side effect is an ophthalmic inflammation-related disorder, e.g., selected from uveitis, conjunctivitis, orbital inflammation, Graves' ophthalmopathy, choroidal neovascularization, optic neuropathy, keratitis, and retinopathy.

[0099] 1.35 Any of the above methods, wherein the subject is suffering from a side effect of immune checkpoint inhibitor therapy, wherein the side effect is a neurological inflammation-related disorder selected from, e.g., encephalopathy, Guillain-Barré syndrome, polyradiculopathy, symmetrical multifocal neuropathy, transverse myelitis, necrotizing myelopathy, myasthenia gravis, phrenic nerve paralysis, immune-related meningitis, meningioradiculoneuritis, peripheral neuropathy, autoimmune inner ear disease, multiple sclerosis, and inflammatory enteric neuropathy.

[0100] 1.36 Any of the above methods, wherein the subject is suffering from a side effect of immune checkpoint inhibitor therapy, wherein the side effect is a hematological inflammation-related disorder, e.g., selected from thrombocytopenia, pancytopenia, neutropenia, eosinophilia, pure red blood cell aplasia, acquired hemophilia A, and disseminated intravascular coagulation.

[0101] 1.37 Any of the above methods, wherein the subject is suffering from a side effect of immune checkpoint inhibitor therapy, wherein the side effect is a urogenital inflammatory associated disorder, e.g., selected from renal failure, acute / granulomatous interstitial nephritis, acute tubular necrosis, and lymphocytic vasculitis (e.g., uterine lymphocytic vasculitis).

[0102] 1.38 Any of the above methods, wherein the subject is suffering from a side effect of immune checkpoint inhibitor therapy, wherein the side effect is a respiratory inflammation-related disorder, e.g., selected from interstitial pneumonia and acute respiratory distress.

[0103] 1.39 Any of the above methods, wherein the subject is suffering from a side effect of immune checkpoint inhibitor therapy, wherein the side effect is a musculoskeletal inflammation-related disorder, e.g., selected from polyarthritis, arthralgia, myalgia, chronic granulomatous inflammation of the rectus abdominis muscle, and rhabdomyolysis.

[0104] 1.40 Any of the above methods, wherein the subject is suffering from a side effect of immune checkpoint inhibitor therapy, wherein the side effect is a cardiac inflammation-related disorder, e.g., selected from precarditis and takotsubo-like syndrome.

[0105] 1.41 Any of the above methods, wherein the subject is suffering from a side effect of immune checkpoint inhibitor therapy, wherein the side effect is a systemic inflammation-related disorder, e.g., selected from pulmonary sarcoidosis, cutaneous and pulmonary sarcoidosis, polymyalgia rheumatica, giant cell arteritis, muscular sarcoidosis, neurological and pulmonary sarcoidosis, celiac disease, lupus nephritis, dermatomyositis, autoimmune inflammatory myopathy, and Vogt-Koyanagi-like syndrome.

[0106] 1.42 Any of the above methods wherein a PDE1 inhibitor is administered before, after or in combination with radiation therapy and / or chemotherapy.

[0107] 1.43 Any of the above methods wherein the PDE1 inhibitor is administered simultaneously with radiation therapy and / or chemotherapy.

[0108] 1.44 Any of the above methods wherein the PDE1 inhibitor is administered prior to radiation therapy and / or chemotherapy.

[0109] 1.45 Any of the above methods wherein the PDE1 inhibitor is administered after radiation therapy and / or chemotherapy.

[0110] 1.46 Any of the above methods, wherein the PDE1 inhibitor is administered in combination with an additional anti-tumor agent, chemotherapeutic treatment, gene therapy treatment and / or immunological treatment.

[0111] 1.47 The PDE1 inhibitor is a PDE1 inhibitor of formula I, Ia, II, III, IV, V and / or VI, or any of the following in free or pharma- ceutically acceptable salt form: [ka] [ka] Any of the above methods, wherein the compound is represented by the formula:

[0112] 1.48 Any of the above methods, wherein the PDE1 inhibitor is a PDE1 inhibitor of formula Ia.

[0113] 1.49 The PDE1 inhibitor is selected from the group consisting of the following, in free form or in pharma- ceutically acceptable salt form: [ka] Any of the above methods, wherein the compound is represented by the formula:

[0114] 1.50 The PDE1 inhibitor is selected from the group consisting of the following in free form or in pharma- ceutically acceptable salt form, e.g., in monophosphate form: [ka] Any of the above methods, wherein the compound is represented by the formula:

[0115] 1.51 Any of the above methods, wherein the PDE1 inhibitor inhibits macrophage or microglia recruitment to metastatic cells.

[0116] 1.52 Any of the above methods, wherein a PDE1 inhibitor inhibits CCL2-mediated macrophage or microglia recruitment to metastatic cells.

[0117] 1.53 For subjects in need of cancer or tumor treatment (i) administering a pharma- ceutically acceptable amount of a PDE1 inhibitor (e.g., a PDE1 inhibitor of Formula I, Ia, II, III, IV, V, and / or VI); and (ii) administering a pharma- ceutically acceptable amount of a checkpoint inhibitor. Any of the above methods, which is a method for treating cancer or tumors comprising:

[0118] 1.54 Any of the above methods further comprising administering to said subject a pharma- ceutically acceptable amount of a beta-blocker.

[0119] 1.55 Any of the above methods comprising administration of a PDE1 inhibitor to a patient undergoing or to undergo immunotherapy (e.g., checkpoint inhibitor and / or CAR-T therapy).

[0120] 1.56 The above method, wherein the immunotherapy is CAR-T therapy.

[0121] In another embodiment, the present disclosure provides a method for producing a pharmaceutical composition comprising: (i) cancer or tumor recruitment of immune cells, such as macrophages (e.g., TAMs or MAMs) and / or microglia, e.g., chemokine-mediated recruitment, e.g., CCL2-mediated recruitment; (ii) tumor or cancer metastasis, e.g., TAM-associated or MAM-associated metastasis; (iii) tumor or cancer angiogenesis, e.g., TAM-associated or MAM-associated angiogenesis; (iv) disruption of tumor or cancer immune surveillance, e.g., disruption of TAM-associated or MAM-associated immune surveillance. For use in inhibiting a PDE1 receptor, for example for use in any of Methods 1 onwards, a PDE1 inhibitor is provided.

[0122] In another embodiment, the present application provides a method for preventing or alleviating a disease, disorder, or adverse effect resulting from checkpoint inhibitor therapy, comprising administering to a subject in need of such prevention or alleviation a pharma- ceutically acceptable amount of a PDE1 inhibitor (i.e., a PDE1 inhibitor represented by Formula I, Ia, II, III, IV, V, and / or VI) (Method 2).

[0123] 2.1 Method 2, wherein the subject is administered checkpoint inhibitor therapy as a treatment for a tumor or cancer.

[0124] 2.2 The above method, wherein the tumor or cancer exhibits increased expression of PDE1 in cancerous or neoplastic cells.

[0125] 2.3 Any of methods 2.1-2.2, wherein the cancerous or neoplastic cell exhibits increased expression of PDE1C in the cancerous or neoplastic cell.

[0126] 2.4 Any of methods 2.1-2.3, wherein the cancer cells exhibit one or more of increased PDE1 RNA expression, DNA copy number, PDE1 binding (e.g., PET or radioisotope loading of a PDE1 inhibitor molecule), modifications to the PDE1 enzyme (e.g., cleavage of the receptor causing loss of calcium / calmodulin control), or PDE1 enzyme activity (e.g., as measured in an enzyme assay or reflected in lower levels of cAMP in the cancer cells or in intracellular domains of the cancer cells, e.g., microtubule domains) compared to normal cells of the same tissue type as the cancer cells.

[0127] 2.5 Any of methods 2.1-2.4, wherein the condition is a tumor.

[0128] 2.6 The tumor is: acoustic neuroma, astrocytoma, chordoma, CNS lymphoma, craniopharyngioma, glioma (e.g., brain stem glioma, ependymoma, mixed glioma, optic nerve glioma), subependymoma, medulloblastoma, meningioma, metastatic brain tumor, oligodendroglioma, pituitary tumor, primitive neuroectodermal tumor (PNET), schwannoma, adenoma (e.g., basophilic adenoma, acidophilic adenoma, chromophobe adenoma, parathyroid adenoma, pancreatic islet adenoma, fibroadenoma), fibroid (fibrous histiocytoma), fibroma, hemangioma, lipoma (e.g., angiolipoma, myelolipoma, fibrolipoma, spindle cell lipoma, brown lipoma, atypical lipoma), myxoma, osteoma, preleukemia, rhabdomyoma rhadomyoma, papilloma, seborrheic keratosis, skin adnexal tumor, hepatic adenoma, renal tubular adenoma, bile duct adenoma, transitional cell papilloma, hydatidiform mole, ganglioneuroma, meningioma, schwannoma, neurofibroma, C-cell hyperplasia, pheochromocytoma, insulinoma, gastrinoma, carcinoid, chemodectoma, paraganglioma, nevus, actinic keratosis, cervical dysplasia, metaplasia (e.g., pulmonary metaplasia), leukoplakia, hemangioma, lymphangioma, carcinoma (e.g., squamous cell carcinoma, epidermoid carcinoma, adenocarcinoma, hepatoma, hepatocellular carcinoma, renal cell carcinoma, cholangiocarcinoma, transitional cell carcinoma, embryonal cell carcinoma cell carcinoma, parathyroid carcinoma, medullary thyroid carcinoma, bronchial carcinoid, oat cell carcinoma, islet cell carcinoma, malignant carcinoid, Merkel cell tumor, colon carcinoma), sarcomas (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, malignant fibrous histiocytoma, hemangiosarcoma, angiosarcoma, lymphangiosarcoma, leiomyosarcoma, rhabdomyosarcoma, neurofibrosarcoma), blastomas (e.g., medulloblastoma and glioblastoma, types of brain tumors) Any of methods 2.1 to 2.5, wherein the tumor is selected from one or more of the following: retinoblastoma, ocular retinal tumor, osteoblastoma, bone tumor, neuroblastoma, germ cell tumor, mesothelioma, malignant skin adnexal tumor, Grawitz tumor, seminoma, glioma, malignant meningioma, malignant Schwannoma, malignant pheochromocytoma, malignant paraganglioma, melanoma, Merkel cell neoplasm, cystosarcoma phylloides, or Wilms tumor.

[0129] 2.7 Any of methods 2.1-2.6, wherein the tumor or cancer is a glioma, lymphoma, osteosarcoma, melanoma, leukemia, or neuroblastoma.

[0130] 2.8 Any of methods 2.1-2.7, wherein the tumor or cancer is a glioma (e.g., ependymoma, astrocytoma, oligodendroglioma, brain stem glioma, optic nerve glioma, or mixed glioma, e.g., oligoastrocytoma).

[0131] 2.9 The above method, wherein the glioma is an astrocytoma (e.g., glioblastoma multiforme).

[0132] 2.10 Any of methods 2.1-2.9, wherein the tumor or cancer is glioblastoma multiforme or lymphoma.

[0133] 2.11 Method 2.1, wherein the condition is cancer.

[0134] 2.12 Any of methods 2.1 or 2.11, wherein the condition is lung cancer, pancreatic cancer, prostate cancer, urothelial cancer, head and neck cancer, or leukemia.

[0135] 2.13 Method 2.12, wherein the leukemia is lymphocytic leukemia or myeloid leukemia.

[0136] 2.14 Method 2.12, wherein the urothelial cancer is a cancer of the kidney, ureter, bladder, or urethra.

[0137] 2.15 Any of the above methods, wherein the checkpoint inhibitor is an inhibitor of CTLA-4, PD-1 and / or PD-L1.

[0138] 2.16 Any of the above methods wherein the checkpoint inhibitor comprises one or more members selected from nivolumab, pembrolizumab, cemiplimab, ipilimumab, avelumab, durvalumab, atezolizumab, and spartalizumab.

[0139] 2.17 Any of the above methods, wherein the checkpoint inhibitor is an inhibitor of CTLA-4.

[0140] 2.18 Any of methods 2 to 2.16, wherein the checkpoint inhibitor is an inhibitor of PD-1.

[0141] 2.19 Any of methods 2 to 2.16, wherein the checkpoint inhibitor is an inhibitor of PD-L1.

[0142] 2.20 Any of the above methods, wherein the checkpoint inhibitor is administered simultaneously with the PDE1 inhibitor.

[0143] 2.21 Any of the above methods, wherein the checkpoint inhibitor is administered prior to administration of the PDE1 inhibitor.

[0144] 2.22 Any of the above methods, wherein the checkpoint inhibitor is administered following administration of the PDE1 inhibitor.

[0145] 2.23 Any of the above methods, wherein the subject in need of said prevention or alleviation has prior or concomitantly been administered checkpoint inhibitor therapy.

[0146] 2.24 Any of the above methods, wherein the subject in need of said prevention or alleviation is suffering from a disease, disorder, or adverse effects of checkpoint inhibitor therapy.

[0147] 2.25 The above method, wherein the subject is suffering from an inflammation-related disorder as a result of checkpoint inhibitor therapy.

[0148] 2.26 Method 2.24 or 2.25, wherein the subject is suffering from a systemic inflammatory response, a gastroenteritis-related disorder, an endocrine inflammation-related disorder, a dermatological inflammation-related disorder, an ophthalmological inflammation-related disorder, a neurological inflammation-related disorder, a hematological inflammation-related disorder, a genitourinary inflammation-related disorder, a respiratory inflammation-related disorder, a musculoskeletal inflammation-related disorder, a cardiac inflammation-related disorder, or a defined systemic inflammation-related disorder.

[0149] 2.27 Method 2.26, wherein the gastroenteritis related disorder is selected from colitis, enterocolitis, colitis complicated by intestinal perforation, hepatitis, and pancreatitis.

[0150] 2.28 Method 2.26, wherein the endocrine inflammation-related disorder is selected from hypophysitis (e.g., presenting with panhypopituitarism), thyrotoxicosis, hypothyroidism, syndrome of inappropriate secretion of antidiuretic hormone, central adrenal insufficiency, primary adrenal insufficiency, and diabetes mellitus.

[0151] 2.29 Method 2.26, wherein the dermatological inflammation-related disorder is selected from rash, pruritus, vitiligo vulgaris, dermatitis, Sweet's syndrome, drug rash, gray hair, delayed hypersensitivity reaction, alopecia universalis, Grover's disease, pyoderma gangrenosum, toxic epidermal necrolysis, chronic noncaseating granuloma, bullous pemphigoid, and psoriasis.

[0152] 2.30 Method 2.26, wherein the ophthalmic inflammation-related disorder is selected from uveitis, conjunctivitis, orbititis, Graves' ophthalmopathy, choroidal neovascularization, optic neuropathy, keratitis, and retinopathy.

[0153] 2.31 Method 2.26, wherein the neurological inflammation-related disorder is selected from encephalopathy, Guillain-Barré syndrome, polyradiculopathy, symmetrical multifocal neuropathy, transverse myelitis, necrotizing myelopathy, myasthenia gravis, phrenic nerve paralysis, immune-related meningitis, meningioradiculoneuritis, peripheral neuropathy, autoimmune inner ear disease, multiple sclerosis, and inflammatory enteric neuropathy.

[0154] 2.32 Method 2.26, wherein the hematological inflammation-related disorder is selected from thrombocytopenia, pancytopenia, neutropenia, eosinophilia, pure red blood cell aplasia, acquired hemophilia A, and disseminated intravascular coagulation.

[0155] 2.33 Method 2.26, wherein the genitourinary inflammatory-related disorder is selected from renal failure, acute / granulomatous interstitial nephritis, acute tubular necrosis, and lymphocytic vasculitis (e.g., uterine lymphocytic vasculitis).

[0156] 2.34 Method 2.26, wherein the respiratory inflammation-related disorder is selected from interstitial pneumonia and acute respiratory distress.

[0157] 2.35 Method 2.26, wherein the musculoskeletal inflammation-related disorder is selected from polyarthritis, arthralgia, myalgia, chronic granulomatous inflammation of the rectus abdominis muscle, and rhabdomyolysis.

[0158] 2.36 Method 2.26, wherein the cardiac inflammation-related disorder is selected from precarditis and takotsubo-like syndrome.

[0159] 2.37 Method 2.26, wherein the defined systemic inflammation-related disorder is selected from pulmonary sarcoidosis, cutaneous and pulmonary sarcoidosis, polymyalgia rheumatica, giant cell arteritis, muscular sarcoidosis, neurological and pulmonary sarcoidosis, celiac disease, lupus nephritis, dermatomyositis, autoimmune inflammatory myopathy, and Vogt-Koyanagi-like syndrome.

[0160] 2.38 Any of the above methods, wherein the PDE1 inhibitor and checkpoint inhibitor are administered in conjunction with radiation therapy or chemotherapy.

[0161] 2.39 Any of the above methods, wherein the PDE1 inhibitor and checkpoint inhibitor are administered simultaneously with radiation therapy or chemotherapy.

[0162] 2.40 Any of the above methods, wherein the PDE1 inhibitor and checkpoint inhibitor are administered prior to radiation therapy or chemotherapy.

[0163] 2.41 Any of the above methods, wherein the PDE1 inhibitor and checkpoint inhibitor are administered after radiation therapy or chemotherapy.

[0164] 2.42 Any of the above methods, wherein the PDE1 inhibitor and checkpoint inhibitor are administered together with an additional anti-tumor agent, chemotherapeutic treatment, gene therapy treatment and / or immunological treatment.

[0165] 2.43 The PDE1 inhibitor is a PDE1 inhibitor of formula I, Ia, II, III, IV, V and / or VI, or the following in free or pharma- ceutically acceptable salt form: [ka] [ka] Any of the above methods, wherein the compound is represented by the formula:

[0166] 2.44 Any of the above methods, wherein the PDE1 inhibitor is a PDE1 inhibitor of formula Ia.

[0167] 2.45 The PDE1 inhibitor is one of the following, in free form or in pharma- ceutically acceptable salt form: [ka] Any of the above methods, wherein the compound is represented by the formula:

[0168] 2.46 The PDE1 inhibitor is selected from the group consisting of the following in free form or in pharma- ceutically acceptable salt form, e.g., the monophosphate form: [ka] Any of the above methods, wherein the compound is represented by the formula:

[0169] 2.47 Any of the above methods further comprising administering to said subject a pharma- ceutically acceptable amount of a beta-blocker.

[0170] 2.48 Any of the above methods comprising administration of a PDE1 inhibitor to a patient undergoing or planning to undergo immunotherapy (e.g., checkpoint inhibitors and / or gene editing or CAR-T therapy).

[0171] 2.49 The above method, wherein the immunotherapy is CAR-T therapy.

[0172] In another embodiment, the disclosure provides a PDE1 inhibitor (e.g., a PDE1 inhibitor represented by Formula I, Ia, II, III, IV, V and / or VI) for use in preventing or alleviating a disease, disorder, or adverse effects resulting from administration of checkpoint inhibitor therapy, e.g., for use in any of Methods 2 onwards.

[0173] In another embodiment, the present application provides a method for inhibiting macrophage or microglia recruitment to metastatic cells (Method 3), comprising administering to a subject in need of such inhibition a pharma- ceutically acceptable amount of a PDE1 inhibitor (e.g., a PDE1 inhibitor represented by Formula I, Ia, II, III, IV, V and / or VI).

[0174] 3.1 Macrophage or microglia recruitment to metastatic cells is mediated by CCL2, Method 3.

[0175] 3.2 Any of the above methods wherein the PDE1 inhibitor is administered in conjunction with a checkpoint inhibitor as a treatment for a tumor or cancer.

[0176] 3.3 The above method, wherein the tumor or cancer exhibits increased expression of PDE1 in cancerous or neoplastic cells.

[0177] 3.4 Any of methods 3.2-3.3, wherein the cancerous or neoplastic cells exhibit increased expression of PDE1C.

[0178] 3.5 Any of methods 3.2-3.4, wherein the cancer cells exhibit one or more of increased PDE1 RNA expression, DNA copy number, PDE1 binding (e.g., PET or radioisotope loading of a PDE1 inhibitor molecule), modifications to the PDE1 enzyme (i.e., cleavage of the receptor causing loss of calcium / calmodulin control), or PDE1 enzyme activity (e.g., as measured by an enzyme assay or reflected by lower levels of cAMP in the cancer cells or in intracellular domains of the cancer cells, e.g., microtubule domains) compared to normal cells of the same tissue type as the cancer cells.

[0179] 3.6 Any of the above methods, wherein the metastatic cell is a tumor or cancer.

[0180] 3.7 The above method, wherein the metastatic cell is a tumor.

[0181] 3.8 The tumor is: acoustic neuroma, astrocytoma, chordoma, CNS lymphoma, craniopharyngioma, glioma (e.g., brain stem glioma, ependymoma, mixed glioma, optic nerve glioma), subependymoma, medulloblastoma, meningioma, metastatic brain tumor, oligodendroglioma, pituitary tumor, primitive neuroectodermal tumor (PNET), schwannoma, adenoma (e.g., basophilic adenoma, acidophilic adenoma, chromophobe adenoma, parathyroid adenoma, pancreatic islet adenoma, fibroadenoma), fibroid (fibrous histiocytoma), fibroma, hemangioma, lipoma (e.g., angiolipoma, myelolipoma, fibrolipoma, spindle cell lipoma, brown lipoma, atypical lipoma), myxoma, osteoma, preleukemia, rhabdomyoma rhadomyoma, papilloma, seborrheic keratosis, skin adnexal tumor, hepatic adenoma, renal tubular adenoma, bile duct adenoma, transitional cell papilloma, hydatidiform mole, ganglioneuroma, meningioma, schwannoma, neurofibroma, C-cell hyperplasia, pheochromocytoma, insulinoma, gastrinoma, carcinoid, chemodectoma, paraganglioma, nevus, actinic keratosis, cervical dysplasia, metaplasia (e.g., pulmonary metaplasia), leukoplakia, hemangioma, lymphangioma, carcinoma (e.g., squamous cell carcinoma, epidermoid carcinoma, adenocarcinoma, hepatoma, hepatocellular carcinoma, renal cell carcinoma, cholangiocarcinoma, transitional cell carcinoma, embryonal cell carcinoma cell carcinoma, parathyroid carcinoma, medullary thyroid carcinoma, bronchial carcinoid, oat cell carcinoma, islet cell carcinoma, malignant carcinoid, Merkel cell tumor, colon carcinoma), sarcomas (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, malignant fibrous histiocytoma, hemangiosarcoma, angiosarcoma, lymphangiosarcoma, leiomyosarcoma, rhabdomyosarcoma, neurofibrosarcoma), blastomas (e.g., medulloblastoma and glioblastoma, types of brain tumors) Any of methods 3.6-3.7, wherein the tumor is selected from one or more of the following: retinoblastoma, ocular retinal tumor, osteoblastoma, bone tumor, neuroblastoma, germ cell tumor, mesothelioma, malignant skin adnexal tumor, Grawitz tumor, seminoma, glioma, malignant meningioma, malignant Schwannoma, malignant pheochromocytoma, malignant paraganglioma, melanoma, Merkel cell neoplasm, cystosarcoma phylloides, or Wilms tumor.

[0182] 3.9 Any of methods 3.6-3.8, wherein the tumor or cancer is a glioma, lymphoma, osteosarcoma, melanoma, leukemia, or neuroblastoma.

[0183] 3.10 Any of methods 3.6-3.9, wherein the tumor or cancer is a glioma (e.g., ependymoma, astrocytoma, oligodendroglioma, brain stem glioma, optic nerve glioma, or mixed glioma, e.g., oligoastrocytoma).

[0184] 3.11 The above method, wherein the glioma is an astrocytoma (e.g., glioblastoma multiforme).

[0185] 3.12 Any of methods 3.6-3.11, wherein the tumor or cancer is glioblastoma multiforme or lymphoma.

[0186] 3.13 The method 3.6, wherein the condition is cancer.

[0187] 3.14 Any of methods 3.6 or 3.13, wherein the condition is lung cancer, pancreatic cancer, prostate cancer, urothelial cancer, head and neck cancer, or leukemia.

[0188] 3.15 Method 3.14, wherein the leukemia is lymphocytic leukemia or myeloid leukemia.

[0189] 3.16 Method 3.14, wherein the urothelial cancer is a cancer of the kidney, ureter, bladder, or urethra.

[0190] 3.17 Any of methods 3.2-3.16, wherein the checkpoint inhibitor is an inhibitor of CTLA-4, PD-1 and / or PD-L1.

[0191] 3.18 Any of Methods 3.2-3.17, wherein the checkpoint inhibitor comprises one or more members selected from nivolumab, pembrolizumab, cemiplimab, ipilimumab, avelumab, durvalumab, atezolizumab, and spartalizumab.

[0192] 3.19 Any of methods 3.2-3.18, wherein the checkpoint inhibitor is an inhibitor of CTLA-4.

[0193] 3.20 Any of methods 3.2-3.18, wherein the checkpoint inhibitor is an inhibitor of PD-1.

[0194] 3.21 Any of methods 3.2 to 3.18, wherein the checkpoint inhibitor is an inhibitor of PD-L1.

[0195] 3.22 Any of the above methods, wherein the checkpoint inhibitor is administered simultaneously with the PDE1 inhibitor.

[0196] 3.23 Any of methods 3.2-3.22, wherein the checkpoint inhibitor is administered prior to administration of the PDE1 inhibitor.

[0197] 3.24 Any of methods 3.2-3.23, wherein the checkpoint inhibitor is administered after administration of the PDE1 inhibitor.

[0198] 3.25 Any of Methods 3.2-3.24, wherein the subject in need of said inhibition has prior or concomitantly been administered checkpoint inhibitor therapy.

[0199] 3.26 Any of Methods 3.2-3.25, wherein the subject in need of said inhibition is suffering from a disease, disorder, or adverse effects of checkpoint inhibitor therapy.

[0200] 3.27 The method above, wherein the subject is suffering from an inflammation-related disorder as a result of checkpoint inhibitor therapy.

[0201] 3.28 Method 3.26 or 3.27, wherein the subject is suffering from a systemic inflammatory response, a gastroenteritis-related disorder, an endocrine inflammation-related disorder, a dermatological inflammation-related disorder, an ophthalmological inflammation-related disorder, a neurological inflammation-related disorder, a hematological inflammation-related disorder, a genitourinary inflammation-related disorder, a respiratory inflammation-related disorder, a musculoskeletal inflammation-related disorder, a cardiac inflammation-related disorder, or a defined systemic inflammation-related disorder.

[0202] 3.29 Method 3.28, wherein the gastroenteritis related disorder is selected from colitis, enterocolitis, colitis complicated by intestinal perforation, hepatitis, and pancreatitis.

[0203] 3.30 Method 3.28, wherein the endocrine inflammation-related disorder is selected from hypophysitis (e.g., presenting with panhypopituitarism), thyrotoxicosis, hypothyroidism, syndrome of inappropriate secretion of antidiuretic hormone, central adrenal insufficiency, primary adrenal insufficiency, and diabetes mellitus.

[0204] 3.31 Method 3.28, wherein the dermatological inflammation-related disorder is selected from rash, pruritus, vitiligo vulgaris, dermatitis, Sweet's syndrome, drug rash, gray hair, delayed hypersensitivity reaction, alopecia universalis, Grover's disease, pyoderma gangrenosum, toxic epidermal necrolysis, chronic noncaseating granuloma, bullous pemphigoid, and psoriasis.

[0205] 3.32 Method 3.28, wherein the ophthalmic inflammation-related disorder is selected from uveitis, conjunctivitis, orbititis, Graves' ophthalmopathy, choroidal neovascularization, optic neuropathy, keratitis, and retinopathy.

[0206] 3.33 Method 3.28, wherein the neurological inflammation-related disorder is selected from encephalopathy, Guillain-Barre syndrome, polyradiculopathy, symmetrical multifocal neuropathy, transverse myelitis, necrotizing myelopathy, myasthenia gravis, phrenic nerve paralysis, immune-related meningitis, meningioradiculoneuritis, peripheral neuropathy, autoimmune inner ear disease, multiple sclerosis, and inflammatory enteric neuropathy.

[0207] 3.34 Method 3.28, wherein the hematological inflammation-related disorder is selected from thrombocytopenia, pancytopenia, neutropenia, eosinophilia, pure red blood cell aplasia, acquired hemophilia A, and disseminated intravascular coagulation.

[0208] 3.35 Method 3.28, wherein the genitourinary inflammatory related disorder is selected from renal failure, acute / granulomatous interstitial nephritis, acute tubular necrosis, and lymphocytic vasculitis (e.g., uterine lymphocytic vasculitis).

[0209] 3.36 The method 3.28, wherein the respiratory inflammation-related disorder is selected from interstitial pneumonia and acute respiratory distress.

[0210] 3.37 Method 3.28, wherein the musculoskeletal inflammation-related disorder is selected from polyarthritis, arthralgia, myalgia, chronic granulomatous inflammation of the rectus abdominis muscle, and rhabdomyolysis.

[0211] 3.38 Method 3.28, wherein the cardiac inflammation-related disorder is selected from precarditis and takotsubo-like syndrome.

[0212] 3.39 Method 3.28, wherein the defined systemic inflammation-related disorder is selected from pulmonary sarcoidosis, cutaneous and pulmonary sarcoidosis, polymyalgia rheumatica, giant cell arteritis, muscular sarcoidosis, neurological and pulmonary sarcoidosis, celiac disease, lupus nephritis, dermatomyositis, autoimmune inflammatory myopathy, and Vogt-Koyanagi-like syndrome.

[0213] 3.40 Any of methods 3.2-3.39, wherein the PDE1 inhibitor and checkpoint inhibitor are administered in conjunction with radiation therapy or chemotherapy.

[0214] 3.41 Any of methods 3.2-3.40, wherein the PDE1 inhibitor and checkpoint inhibitor are administered simultaneously with radiation therapy or chemotherapy.

[0215] 3.42 Any of methods 3.2-3.41, wherein the PDE1 inhibitor and checkpoint inhibitor are administered prior to radiation therapy or chemotherapy.

[0216] 3.43 Any of methods 3.2-3.42, wherein the PDE1 inhibitor and checkpoint inhibitor are administered following radiation therapy or chemotherapy.

[0217] 3.44 Any of methods 3.2-3.43, wherein the PDE1 inhibitor and checkpoint inhibitor are administered together with an additional anti-tumor agent, chemotherapeutic treatment, gene therapy treatment and / or immunological treatment.

[0218] 3.45 The PDE1 inhibitor is a PDE1 inhibitor of formula I, Ia, II, III, IV, V and / or VI, or the following in free or pharma- ceutically acceptable salt form: [ka] [ka] Any of the above methods, wherein the compound is represented by the formula:

[0219] 3.46 Any of the above methods, wherein the PDE1 inhibitor is a PDE1 inhibitor of formula Ia.

[0220] 3.47 The PDE1 inhibitor is any of the following, in free form or in pharma- ceutically acceptable salt form: [ka] Any of the above methods, wherein the compound is represented by the formula:

[0221] 3.48 The PDE1 inhibitor is selected from the group consisting of the following in free form or in pharma- ceutically acceptable salt form, e.g., monophosphate form: [ka] Any of the above methods, wherein the compound is represented by the formula:

[0222] 3.49 Any of the above methods, further comprising administering to said subject a pharma- ceutically acceptable amount of a beta-blocker.

[0223] 3.50 Any of the above methods comprising administration of a PDE1 inhibitor to a patient undergoing or to undergo immunotherapy (i.e., CAR-T therapy).

[0224] 3.51 The above method, wherein the immunotherapy is CAR-T therapy.

[0225] Combination therapy with PDE1 inhibitors In another embodiment, the disclosure provides a PDE1 inhibitor (eg, a PDE1 inhibitor having formula I, Ia, II, III, IV, V, and / or VI).

[0226] Use of inhibiting macrophage or microglia recruitment to metastatic cells, comprising administering a pharma- ceutically acceptable amount of

[0227] In some embodiments, PDE1 inhibitor is administered in combination with other treatment modalities.Therefore, in the treatment of disease or disorder according to the present disclosure, more pharmaceutical therapy can be provided to the patient.Examples of other treatments include, for example, checkpoint inhibitors.A particular form of combination therapy includes the use of PDE1 inhibitors.

[0228] The combination can be achieved by administering a single composition or pharmacological formulation containing the PDE1 inhibitor and one or more additional therapeutic agents, or by administering two different compositions or formulations separately, simultaneously, or sequentially, one composition containing the PDE1 inhibitor and the other containing the additional therapeutic agent. Treatment with the PDE1 inhibitor may precede or follow administration of the other agent by an interval ranging from minutes to weeks. In embodiments in which the other agent and the expression construct are applied to the cells separately, one generally ensures that no significant time passes between each delivery, so that the agent and the expression construct can still exert their beneficial combined effect on the cells. In some embodiments, it is contemplated that the cells will typically be contacted with both modalities within about 12-24 hours of each other, more preferably within about 6-12 hours of each other, with a delay time of only about 12 hours being most preferred. However, in some circumstances, it may be desirable to extend the treatment period significantly, with days (2, 3, 4, 5, 6, or 7) to weeks (1, 2, 3, 4, 5, 6, 7, or 8) passing between the respective administrations.

[0229] It is also contemplated that it may be desirable to administer either the PDE1 inhibitor or the additional therapeutic agent more than once. In this regard, various combinations may be used. By way of example, where the PDE1 inhibitor is "A" and the additional therapeutic agent is "B", the following permutations based on a total of three and four administrations are exemplified: [ka]

[0230] Thus, in various embodiments, the disclosure also provides pharmaceutical combination [combination 1] therapies comprising a pharma- ceutically effective amount of a PDE1 inhibitor (e.g., a compound of Formula I, Ia, II, III, IV, V and / or VI) and a checkpoint inhibitor for administration in a method for treating a condition selected from cancer or tumor, e.g., according to any of Methods 1 et seq., or for preventing or reducing a disease, disorder or adverse effects resulting from administration of a checkpoint inhibitor therapy, e.g., according to any of Methods 2 et seq., or for inhibiting macrophage or microglia recruitment to metastatic cells, e.g., according to any of Methods 3 et seq. For example, the disclosure provides the following combinations:

[0231] 1.1 Combination 1, in which the PDE1 inhibitor and the checkpoint inhibitor are contained in a single dosage form, such as a tablet or capsule, together or in association with a pharma- ceutically acceptable diluent or carrier.

[0232] 1.2 Combination 1, in which the PDE1 inhibitor and the checkpoint inhibitor are contained in a single package, e.g., containing instructions for simultaneous or sequential administration.

[0233] 1.3 The PDE1 inhibitor is a PDE1 inhibitor of formula I, Ia, II, III, IV, V and / or VI, or the following in free or pharma- ceutically acceptable salt form: [ka] [ka] Any of the above methods, wherein the compound is represented by the formula:

[0234] 1.4 Any of the above methods, wherein the PDE1 inhibitor is a PDE1 inhibitor of formula Ia:

[0235] 1.5 The PDE1 inhibitor is selected from the group consisting of the following, in free form or in pharma- ceutically acceptable salt form: [ka] Any of the above methods, wherein the compound is represented by the formula:

[0236] 1.6 The PDE1 inhibitor is selected from the group consisting of the following, in free form or in pharma- ceutically acceptable salt form: [ka] Any of the above methods, wherein the compound is represented by the formula:

[0237] 1.7 Any of the above combinations wherein the checkpoint inhibitor is an inhibitor of CTLA-4, PD-1 and / or PD-L1.

[0238] 1.8 Any of the above combinations where the checkpoint inhibitor includes one or more members selected from nivolumab, pembrolizumab, cemiplimab, ipilimumab, avelumab, durvalumab, atezolizumab, and spartalizumab.

[0239] 1.9 Any of the above combinations wherein the checkpoint inhibitor is an inhibitor of CTLA-4.

[0240] 1.10 Any of Combinations 1-1.8, wherein the checkpoint inhibitor is an inhibitor of PD-1.

[0241] 1.11 Any of Combinations 1-1.8 wherein the checkpoint inhibitor is an inhibitor of PD-L1.

[0242] 1.12 Any of the above combinations where the checkpoint inhibitor is administered simultaneously with the PDE1 inhibitor. 1.13 Any of the above combinations, wherein the checkpoint inhibitor is administered prior to administration of the PDE1 inhibitor.

[0243] 1.14 Any of the above combinations, wherein the checkpoint inhibitor is administered following administration of the PDE1 inhibitor.

[0244] 1.15 Any of the above combinations, wherein a subject in need thereof has prior or concomitantly been administered checkpoint inhibitor therapy.

[0245] 1.16 Any of the above combinations further comprising a pharma- ceutically acceptable amount of a beta-blocker.

[0246] In some embodiments, the pharmaceutical compositions are administered in combination with one or more anti-tumor drugs, such as drugs known to be effective in treating or eliminating various types of cancers and / or tumors. Non-limiting examples of antineoplastic agents include abemaciclib, abiraterone acetate, Abitrexate (methotrexate), Abraxane (paclitaxel-albumin stabilized nanoparticle formulation), ABVD, ABVE, ABVE-PC, AC, acalabrutinib, AC-T, Adcetris (brentuximab vedotin), ADE, ado-trastuzumab emtansine, Adriamycin (doxorubicin hydrochloride), afatinib dimaleate, Afinitor (everolimus), Akynzeo (netupitant-palonosetron hydrochloride), Aldara (imiquimod), aldesleukin, Alecensa (alectinib), alectinib, alemtuzumab, Alimta (pemetidine), methotrexed disodium), Aliqopa (copanlisib hydrochloride), Alkeran for injection (melphalan hydrochloride), Alkeran tablets (melphalan), Aloxi (palonosetron hydrochloride), Alunbrig (brigatinib), Ambochlorin (chlorambucil), Amboclorin (chlorambucil), Amifostine, aminolevulinic acid, anastrozole, aprepitant, Aredia, pamidronate disodium), Arimidex (anastrozole), Aromasin (exemestane), Alanone (nelarabine), arsenic trioxide, Arzera (ofatumumab), asparaginase derived from blackleg fungus Erwinia chrysanthemi), Atezolizumab, Avastin (bevacizumab), Avelumab, Axicabtagene ciloleucel, Axitinib, Azacitidine, Bavencio (avelumab), BEACOPP, Becenum (carmustine), Beleodak (belinostat), Belinostat, Bendamustine hydrochloride, BEP, Besponsa (inotuzumab ozogamicin), Bevacizumab, Bexarotene, Bicalutamide, BiCNU (carmustine), Bleomycin, Blincyto (blinatumomab), Bortezomib, Bosulif (bosutinib),Bosutinib, Brentuximab vedotin, Brigatinib, BuMel, Busulfan, Busulfex (Busulfan), Cabazitaxel, Cabometyx (Cabozantinib S-Malate), Cabozantinib S-Malate, CAF, Calquence (Acalabrutinib), Campus (Alemtuzumab), Camptosar (Irinotecan Hydrochloride), Capecitabine, CAPOX, Carac (Fluorouracil-Topical), Carboplatin, Carboplatin-Taxol, Carfilzomib, Cal Carmubris (carmustine), carmustine, carmustine implant, Casodex (bicalutamide), CEM, ceritinib, Cerubidine (daunorubicin hydrochloride), Cervarix (recombinant HPV bivalent vaccine), cetuximab, CEV, chlorambucil, chlorambucil-prednisone, CHOP, cisplatin, cladribine, Clafen (cyclophosphamide), clofarabine, Clofarex (clofarabine), chloral (Clo lar (clofarabine), CMF, cobimetinib, Cometriq (cabozantinib S-malate), copanlisib hydrochloride, COPDAC, COPP, COPP-ABV, Cosmegen (datinomycin), Cotellic (cobimetinib), crizotinib, CVP, cyclophosphamide, Cyfos (ifosfamide), Cyramza (ramucirumab), cytarabine, cytarabine liposomal, Cytosar-U (cytarabine), Cytoxan (cyclophosphamide), dabrafenib, dacarbazine , Dacogen (decitabine), datinomycin, daratumumab, Darzalex (daratumumab), dasatinib, daunorubicin hydrochloride, daunorubicin hydrochloride and cytarabine liposome, decitabine, defibrotide sodium, Defitelio (defibrotide sodium), degarelix, denileukin diftitox, denosumab, Depocyto (cytarabine liposome), dexamethasone, dexrazoxane hydrochloride, dinutuximab, docetaxel, Doxil (doxorubicin hydrochloride liposome), doxorubicin hydrochloride,Doxorubicin hydrochloride liposome, Dox-SL (doxorubicin hydrochloride liposome), DTIC-Dome (dacarbazine), durvalumab, Efudex (fluorouracil - topical), Elitek (rasburicase), Ellence (epirubicin hydrochloride), elotuzumab, Eloxatin (oxaliplatin), eltrombopag olamine, Emend (aprepitant), Emplivity (elotuzumab), enasidenib mesylate, enzalutamide, epirubicin hydrochloride, EPOCH, Erbitux (cetuximab), eribulin mesylate, Erivedge (vismodegib), erlotinib hydrochloride, Erwinaze (Asparaginase Erwinia chrysanthemi), Ethyol (amifostine), Etopophos (etoposide phosphate), Etoposide, Etoposide phosphate, Evacet (doxorubicin hydrochloride liposomal), Everolimus, Evista (raloxifene hydrochloride), Evomela (melphalan hydrochloride), Exemestane, 5-FU (fluorouracil injection), 5-FU (fluorouracil - topical), Phenobarbital Aston (toremifene), Faridak (panobinostat), Faslodex (fulvestrant), FEC, Femara (letrozole), filgrastim, Fludara (fludarabine phosphate), fludarabine phosphate, Fluoroplex (fluorouracil-topical), fluorouracil injection, fluorouracil-topical, flutamide, Folex (methotrexate), Folex PFS PFS) (methotrexate), Forfili, Forfili-bevacizumab, Forfili-cetuximab, Forfirinox, Forfox, Forothin (pralatrexate), FU-LV, fulvestrant, Gardasil (recombinant HPV quadrivalent vaccine), Gardasil 9 (recombinant HPV nonavalent vaccine), Gazyva (obinutuzumab), gefitinib, gemcitabine hydrochloride, gemcitabine-cisplatin, gemcitabine-oxaliplatin, gemtuzumab ozogamicin,Gemzar (gemcitabine hydrochloride), Gilotrif (afatinib dimaleate), Glivec (imatinib mesylate), Gliadel (carmustine implant), Gliadel wafer (carmustine implant), glucarpidase, goserelin acetate, Halaven (eribulin mesylate), Hemangeol (propranolol hydrochloride), Herceptin (trastuzumab), recombinant HPV bivalent vaccine, recombinant HPV nonavalent vaccine, recombinant HPV quadrivalent vaccine, Hycamtin (topotecan hydrochloride), Hydrea (hydroxyurea), hydroxyurea, Hyper-CVAD, Ibrance (palbociclib), ibritumomab tiuxetan, ibrutinib Tinib, ICE, Iclusig (ponatinib hydrochloride), Idamycin (idarubicin hydrochloride), idarubicin hydrochloride, idelalisib, Idhifa (enasidenib mesylate), Ifex (ifosfamide), ifosfamide, Ifosfamidum (ifosfamide), IL-2 (aldesleukin), imatinib mesylate, Imbruvica (ibrutinib), Imfinzi (durvalumab), imiquimod, Imlygic (talimogene laherparepvec), Inlyta (axitinib), inotuzumab ozogamicin, recombinant interferon alpha-2b, interleukin-2 (aldesleukin), Intron A A) (recombinant interferon alpha-2b), ipilimumab, Iressa (gefitinib), irinotecan hydrochloride, irinotecan hydrochloride liposomal, Istodax (romidepsin), ixabepilone, ixazomib citrate, Ixempra (ixabepilone), Jakafi (ruxolitinib phosphate), JEB, Jevtana (cabazitaxel), Kadcyla (ado-trastuzumab emtansine), Keoxifene (raloxifene hydrochloride), Kepivans (palifermin), Keytruda (pembrolizumab), Kisqali (ribociclib), Kymriah (tisagenlecleucel), Kyprolis (carfilzomib), lanreotide acetate, lapatinib ditosylate,Lartruvo (olaratumab), lenalidomide, lenvatinib mesylate, Lenvima (lenvatinib mesylate), letrozole, leucovorin calcium, Leukeran (chlorambucil), leuprolide acetate, Leustatin (cladribine), Levulan (aminolevulinic acid), Linfolizin (chlorambucil), LipoDox (doxorubicin hydrochloride liposomal), lomustine, Lonsurf (trifluridine and tipiracil hydrochloride), Lupron (leuprolide), Leuprolide acetate), Leuprolide Depot (Leuprolide acetate), Leuprolide Depot-Ped (Leuprolide acetate), Lynparza (Olaparib), Marqibo (Vincristine sulfate liposomal), Matulane (Procarbazine hydrochloride), Mechlorethamine hydrochloride, Megestrol acetate, Mekinist (Trametinib), Melphalan, Melphalan hydrochloride, Mercaptopurine, Mesna, Mesnex (Mesna), Methazolastone (Temozolomide), Methotrexate, Methotrexate LPF (Methotrexate), Methylnaltrexone Bromide, Mexate (Methotrexate), Mexate-AQ (Methotrexate), Midostaurin, Mitomycin C, Mitoxantrone Hydrochloride, Mitozytrex (Mitomycin C), MOPP, Mozovir (Plerixafor), Mustargen (Mechlorethamine Hydrochloride), Mutamycin (Mitomycin C), Myleran (Busulfam) Mylosar (azacitidine), Mylotarg (gemtuzumab-ozogamicin), nanoparticle paclitaxel (paclitaxel-albumin-stabilized nanoparticle formulation), Navelbine (vinorelbine tartrate), necitumumab, nelarabine, Neosar (cyclophosphamide), neratinib maleate, Nerlynx (neratinib maleate), netupitant-palonosetron hydrochloride, Neulasta (pegfilgrastim), Neupogen (filgrastim),Nexavar (sorafenib tosylate), Nilandron (nilutamide), nilotinib, nilutamide, Ninlaro (ixazomib citrate), niraparibut tosylate monohydrate, nivolumab, Nolvadex (tamoxifen citrate), Nplate (romiplostim), obinutuzumab, Odomzo (sonidegib), OEPA, ofatumumab, OFF, olaparib, olaratumab, omacetaxine mepesuccinate, Oncas Oncaspar (Pegaspagase), Ondansetron Hydrochloride, Onivyde (Irinotecan Hydrochloride Liposomal), Ontak (Denileukin Diftitox), Opdivo (Nivolumab), OPPA, Osimertinib, Oxaliplatin, Paclitaxel, Paclitaxel Albumin Stabilized Nanoparticle Formulation, PAD, Palbociclib, Palifermin, Palonosetron Hydrochloride, Palonosetron Hydrochloride and Netu, Pitant, pamidronate disodium, panitumumab, panobinostat, Paraplat (carboplatin), Paraplatin (carboplatin), pazopanib hydrochloride, PCV, PEB, pegaspargase, pegfilgrastim, peginterferon alfa-2b, PEG-Intron (peginterferon alfa-2b), pembrolizumab, pemetrexed disodium, perjeta (Pertuzumab), Pertuzumab, Platinol (cisplatin), Platinol-AQ (cisplatin), Plerixafor, Pomalidomide, Pomalyst (pomalidomide), Ponatinib hydrochloride, Portraza (necitumumab), Pralatrexate, Prednisone, Procarbazine hydrochloride, Proleukin (aldesleukin), Prolia (denosine (eltrombopagulamine), Promacta (eltrombopagulamine), propranolol hydrochloride, Provenzi (sipuleucel-T), Purinethol (mercaptopurine), Purixan (mercaptopurine), radium-223 dichloride, raloxifene hydrochloride, ramucirumab, rasburicase, R-CHOP, R-CVP, recombinant human papillomavirus (HPV) bivalent vaccine, recombinant Human papillomavirus (HPV) nonavalent vaccine, recombinant human papillomavirus (HPV) quadrivalent vaccine, recombinant interferon alpha-2b, regorafenib, Relistol (methylnaltrexone bromide), R-EPOCH, Revlimid (lenalidomide), Rheumatrex (methotrexate), ribociclib, R-ICE, Rituxan (rituximab), Rituxan Hycera Hycela (Rituximab and Human Hyaluronidase), Rituximab, Rituximab and Human Hyaluronidase, Rolapitant Hydrochloride, Romidepsin, Romiplostim, Rubidomycin (Daunorubicin Hydrochloride), Rubraca (Rucaparib Camsylate), Rucaparib CamsylateCamsylate, Ruxolitinib Salt, Rydapt (Midostaurin), Sclerosol Intrapleural Aerosol (Talc), Siltuximab, Sipuleucel-T, Somatuline Depot (Lanreotide Acetate), Sonidegib, Sorafenib Tosylate, Sprycel (Dasatinib), Stanford V, Sterile Talc Powder Powder) (talc), Steritalc (talc), Stivarga (regorafenib), Sunitinib malate, Sutent (sunitinib malate), Sylatron (peginterferon alfa-2b), Sylvant (siltuximab), Synribo (omacetaxine-mepesuccinate), Tabloid (thioguanine), TAC, Tafinlar (dabrafenib), Tagrisso (osimertinib), Talc, Talimogene-laherparepvec, Tamoxifen citrate, Tarabine PFSPFS) (cytarabine), Tarceva (erlotinib hydrochloride), Targretin (bexarotene), Tasigna (nilotinib), Taxol (paclitaxel), Taxotere (docetaxel), Tecentriq (atezolizumab), Temodar (temozolomide), temozolomide, temsirolimus, Thalidomide, Thalomid (thalidomide), Oguanine, Thioteba, Tisagenlecleucel, Tolak (fluorouracil-topical), Topotecan hydrochloride, Toremifene, Torisel (temsirolimus), Totect (dexrazoxane hydrochloride), TPF, Trabectedin, Trametinib, Trastuzumab, Treanda (bendamustine hydrochloride), Trifluridine and Tipiracil hydrochloride, Lysenox (arsenous trioxide), Tykerb (lapatinib ditosylate), Unituxin (dinutuximab), uridine triacetate, VAC, Valrubicin, Valstar (valrubicin), vandetanib, VAMP, Varubi (rolapitant hydrochloride), Vectibix (panitumumab), VeIP, Velban (vinblastine sulfate), Velcade (bortezomib), Velsar (vinblastine sulfate), vemurafenib, Venclexta (venetoclax), venetoclax, Verzenio (abemaciclib), Viadur (leuprolide acetate), Vidaza (azacitidine), vinblastine sulfate, Vincasar PFSPFS) (vincristine sulfate), vincristine sulfate, vincristine sulfate liposomal, vinorelbine tartrate, VIP, vismodegib, Vistogard (uridine triacetate), Voraxaze (glucarpidase), vorinostat, Votrient (pazopanib hydrochloride), Vyxeos (daunorubicin hydrochloride and cytarabine liposomal), Wellcovorin (leucovorin calcium), Xalkori (crizotinib), Xeloda (capecitabine), XELIRI, XELOX, Xgeva (denosumab), Xofigo (radium-223 dichloride), Xtandi (enzalutamide), Yervoy ( These include: ipilimumab), Yescarta (axicabtagene ciloleucel), Yondelis (trabectedin), Zartrap (Ziv-aflibercept), Zarxio (filgrastim), Zejula (niraparibut tosylate monohydrate), Zelboraf (vemurafenib), Zevalin (ibritumomab tiuxetan), Zinecard (dexrazoxane hydrochloride), Ziv-aflibercept, Zofran (ondansetron hydrochloride), Zoladex (goserelin acetate), zoledronic acid, Zolinza (vorinostat), Zometa (zoledronic acid), Zydelig (idelalisib), Zykadia (ceritinib), and Zytiga (abiraterone acetate).

[0247] In some embodiments, PDE1 inhibitor is administered in combination with one or more β-blockers.A non-exhaustive list of such β-blockers includes various β-adrenergic receptor antagonists, also called β-blockers, which are currently used clinically to eliminate the harmful chronic myocardial stimulation caused by failing heart. Preferred beta-adrenergic receptor antagonists include metoprolol, metoprolol succinate, carvedilol, atenolol, propranolol, acebutolol, acebutolol HCL, betaxolol, betaxolol HCL, nadolol, talinolol, bisoprolol, bisoprolol hemifumarate, carteolol, carteolol HCL, esmolol, esmolol HCL, labetalol, labetalol HCL, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, penbutolol, penbutolol sulfate, pindolol, propranolol, propranolol HCL, sotalol, sotalol HCL, timolol, and timolol hydrogen maleate salt, or a pharma- ceutically acceptable salt thereof. In accordance with the present invention, the beta-adrenergic receptor antagonists can be administered in a daily dose that is clinically accepted for such drugs. For example, a suitable daily dose for metoprolol as the tartrate or succinate is about 100-200 mg, and for carvedilol about 5-50 mg, depending on the condition to be treated, the route of administration, and the age, weight and condition of the patient.

[0248] As used herein, the term "anti-tumor agent" is understood to refer to a chemical agent or drug that is effective in preventing or inhibiting the formation or growth of cancer or tumors. Anti-tumor agents discussed herein may include alkylating agents, antimetabolites, natural products, hormones, and / or antibodies. Treating tumors or cancer may include limiting the proliferation, migration, and / or invasion of cancerous or neoplastic cells in the body, or limiting symptoms associated with said cancer or tumor. As used herein, anti-tumor agents include anti-cancer agents, and are otherwise understood to be synonymous with anti-cancer agents.

[0249] Methods for producing the disclosed compounds

[0250] The PDE1 inhibitors and pharma- ceutically acceptable salts thereof of the present disclosure are described in U.S. Patent No. 8,273,750, U.S. Patent Application Publication No. 2006 / 0173878, U.S. Patent No. 8,273,751, U.S. Patent Application Publication No. 2010 / 0273753, U.S. Patent No. 8,697,710, U.S. Patent No. 8,664,207, U.S. Patent No. 8,633,180, U.S. Patent No. 8,536,159, U.S. Patent Application Publication No. 2012 / 0136013, U.S. Patent Application Publication No. 201 ... The starting materials for these processes can be prepared by using methods as described and exemplified in US Patent Publication No. 81832, US Patent Publication No. 2013 / 0085123, US Patent Publication No. 2013 / 0324565, US Patent Publication No. 2013 / 0338124, US Patent Publication No. 2013 / 0331363, WO 2012 / 171016 and WO 2013 / 192556, or by methods similar thereto, and by methods known in the chemical arts. Such methods include, but are not limited to, the methods described below. The starting materials for these processes, if not commercially available, can be prepared by procedures selected from chemical techniques using techniques similar or similar to those used for the synthesis of known compounds.

[0251] Various PDE1 inhibitors and starting materials thereof are disclosed in U.S. Patent Application Publication No. 2008-0188492 (A1), U.S. Patent Application Publication No. 2010-0173878 (A1), U.S. Patent Application Publication No. 2010-0273754 (A1), U.S. Patent Application Publication No. 2010-0273753 (A1), WO 2010 / 065153, WO 2010 / 065151, WO 2010 / 0 The compounds can be prepared using the methods described in WO 2010 / 065149, WO 2010 / 065147, WO 2010 / 065152, WO 2011 / 153129, WO 2011 / 133224, WO 2011 / 153135, WO 2011 / 153136, WO 2011 / 153138. All references cited herein are incorporated by reference in their entirety.

[0252] The disclosed compounds include their enantiomers, diastereomers and racemates, as well as their polymorphs, hydrates, solvates and complexes.Some individual compounds within the scope of the disclosure may contain double bonds.The expression of double bonds in the disclosure is meant to include both the E and Z isomers of the double bond.In addition, some compounds within the scope of the disclosure may contain one or more asymmetric centers.The disclosure includes the use of any of the optically pure stereoisomers, and combinations of stereoisomers.

[0253] It is also intended that the disclosed compounds encompass their stable and unstable isotopes. Stable isotopes are non-radioactive isotopes that contain one additional neutron compared to the abundant nuclide of the same species (i.e., element). The activity of compounds containing such isotopes is retained, and such compounds are also believed to have utility for measuring the pharmacokinetics of non-isotopic analogs. For example, hydrogen atoms at certain positions of the disclosed compounds can be replaced with deuterium (a non-radioactive stable isotope). Examples of known stable isotopes include deuterium, 13 C. 15 N, 18Alternatively, unstable isotopes, which are radioisotopes that contain additional neutrons compared to the abundant nuclide of the same species (i.e., element), e.g. 123 I, 131 I, 125 I, 11 C. 18 F may be replaced by the corresponding abundant species of I, C, and F. Another example of a useful isotope of the compounds of the present disclosure is: 11 C isotope. These radioisotopes are useful for radioimaging and / or pharmacokinetic studies of the compounds of the present disclosure.

[0254] Melting points are uncorrected and (dec) indicates decomposition. Temperatures are given in degrees Celsius (°C); unless otherwise stated, operations are performed at room or ambient temperature, i.e., at temperatures in the range 18-25°C. Chromatography means silica gel flash chromatography; thin layer chromatography (TLC) is performed on silica gel plates. NMR data are given in delta values ​​of major diagnostic protons expressed in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard. Conventional abbreviations for signal shapes are used. Coupling constants (J) are expressed in Hz. For mass spectra (MS), the major ion of lowest mass is reported for molecules where isotopic splitting gives rise to multiple mass spectral peaks. Compositions of solvent mixtures are given as volume percentages or volume ratios. In cases where the NMR spectra are complex, only diagnostic signals are reported.

[0255] The terms "treatment" and "treating" should therefore be understood to include treatment or amelioration of symptoms of disease as well as treatment of the cause of the disease.

[0256] With respect to treatment methods, the term "effective amount" is intended to encompass a therapeutically effective amount for treating a particular disease or disorder.

[0257] The terms "patient" or "subject" include human or non-human (i.e., animal) patients and are understood to be interchangeable within the context of this disclosure. In certain embodiments, the disclosure encompasses both humans and non-humans. In other embodiments, the disclosure encompasses non-humans. In other embodiments, the terms encompass humans.

[0258] The term "comprising" is used in this disclosure to be intended to be open-ended and does not exclude additional, unrecited elements or method steps.

[0259] Dosages used in practicing the present disclosure will of course vary depending, for example, on the particular disease or condition being treated, the particular disclosed compound used, the mode of administration, and the desired therapy. The disclosed compounds may be administered by any suitable route, including orally, parenterally, transdermally, or by inhalation, but are preferably administered orally. In general, satisfactory results, for example for the treatment of diseases such as those mentioned above, have been shown to be obtained by oral administration at doses on the order of about 0.01 to 2.0 mg / kg. In large mammals, such as humans, the indicated daily dose for oral administration of both PDE1 inhibitors is therefore in the range of about 0.50 to 300 mg, conveniently administered once a day or in divided doses two to four times a day, or administered in sustained release dosage form. Thus, a unit dosage form for oral administration can contain, for example, about 0.2 to 150 or 300 mg, for example about 0.2 or 2.0 to 10, 25, 50, 75, 100, 150 or 200 mg of the disclosed compound together with a pharma- ceutically acceptable diluent or carrier.

[0260] The disclosed compounds can be administered by any suitable route, including orally, parenterally (intravenously, intramuscularly or subcutaneously) or transdermally, but are preferably administered orally. In certain embodiments, the disclosed compounds, for example in depot formulations, are preferably administered parenterally, for example by injection.

[0261] The disclosed compounds and pharmaceutical compositions can be used in combination with one or more additional therapeutic agents, particularly at lower doses than when the individual agents are used as monotherapy, to enhance the therapeutic activity of the combined agents without causing undesirable side effects that typically occur with conventional monotherapy.Thus, the disclosed compounds can be administered simultaneously, separately, sequentially, or contemporaneously with other agents useful for treating disease.In another example, side effects can be reduced or minimized by administering the disclosed compounds in combination with one or more additional therapeutic agents in free or salt form, where (i) the dose of the second therapeutic agent or (ii) the dose of both the disclosed compounds and the second therapeutic agent is lower than when the agents / compounds are administered as monotherapy.

[0262] The term "concurrently" when referring to therapeutic use means that two or more active ingredients are administered at the same time or at about the same time and by the same route of administration.

[0263] The term "separately" when referring to therapeutic use means that two or more active ingredients are administered simultaneously or at about the same time by different routes of administration.

[0264] Pharmaceutical compositions containing the disclosed compounds can be prepared using conventional diluents or excipients and techniques known in the galenic art. Thus, oral dosage forms can include tablets, capsules, solutions, suspensions, etc. EXAMPLES

[0265] Example 1 Measurement of PDEIB inhibition in vitro using the IMAP phosphodiesterase assay kit Phosphodiesterase IB (PDEIB) is a calcium / calmodulin-dependent phosphodiesterase enzyme that converts cyclic guanosine monophosphate (cGMP) to 5'-guanosine monophosphate (5'-GMP). PDEIB can also convert modified cGMP substrates, such as the fluorescent molecule cGMP-fluorescein, to the corresponding GMP-fluorescein. The production of GMP-fluorescein from cGMP-fluorescein can be quantified, for example, using the IMAP (Molecular Devices, Sunnyvale, CA) immobilized metal affinity particle reagent.

[0266] Briefly, IMAP reagents bind with high affinity to the free 5'-phosphate present in GMP-fluorescein but absent in cGMP-fluorescein. The resulting GMP-fluorescein-IMAP complex is large relative to cGMP-fluorescein. Small fluorophores bound to the large, slowly tumbling complex can be distinguished from unbound fluorophores because the photons emitted when they fluoresce retain the same polarity as the photons used to excite the fluorescence.

[0267] In the phosphodiesterase assay, cGMP-fluorescein, which cannot bind to IMAP and therefore retains little fluorescence polarization, is converted to GMP-fluorescein, which upon binding to IMAP leads to a large increase in fluorescence polarization (Amp). Thus, inhibition of phosphodiesterase is detected as a decrease in Amp.

[0268] Enzyme assays Materials: All chemicals are available from Sigma-Aldrich (St. Louis, MO), except for IMAP reagents (reaction buffer, binding buffer, FL-GMP and IMAP beads) which are available from Molecular Devices (Sunnyvale, CA).

[0269] Assay: The following phosphodiesterase enzymes can be used: 3',5'-cyclic nucleotide specific bovine brain phosphodiesterase (Sigma, St. Louis, MO) (mainly PDEIB) and recombinant full-length human PDE1A and PDE1B (r-hPDE1A and r-hPDE1B, respectively) (can be produced, for example, in HEK cells or SF9 cells by those skilled in the art). PDE1 enzyme is reconstituted with 50% glycerol to 2.5U / ml. One unit of enzyme hydrolyzes 1.0μM 3',5'-cAMP to 5'-AMP per minute at pH 7.5 and 30℃. One part enzyme is added to 1999 parts reaction buffer (30 μM CaCl2, 10 U / ml calmodulin (Sigma P2277), 10 mM Tris-HCl pH 7.2, 10 mM MgCl2, 0.1% BSA, 0.05% NaN3) to give a final concentration of 1.25 mU / ml. 99 μl of the diluted enzyme solution is added to each well of a flat-bottom 96-well polystyrene plate, to which 1 μL of test compound dissolved in 100% DMSO is added. Compounds are mixed and pre-incubated with the enzyme for 10 minutes at room temperature.

[0270] In a 384-well microtiter plate, FL-GMP conversion reaction is initiated by combining 4 parts of enzyme and inhibitor mixture with 1 part of substrate solution (0.225 μM). The reaction is incubated at room temperature in the dark for 15 minutes. The reaction is stopped by adding 60 μL of binding reagent (IMAP beads at 1:400 dilution in binding buffer with antifoam at 1:1800 dilution) to each well of the 384-well plate. The plate is incubated at room temperature for 1 hour to allow IMAP binding to proceed to completion, and then placed in an Envision multimode microplate reader (PerkinElmer, Shelton, CT) to measure fluorescence polarization (Amp).

[0271] A decrease in GMP concentration, measured as a decrease in Amp, indicates inhibition of PDE activity. The IC was calculated by measuring enzyme activity in the presence of 8 to 16 concentrations of compound ranging from 0.0037 nM to 80,000 nM and then plotting drug concentration versus AMP. 50 IC values ​​were determined using nonlinear regression software (XLFit; IDBS, Cambridge, MA). 50 The value can be estimated.

[0272] The compounds of the present invention are tested in assays described herein or similarly described for PDE1 inhibitory activity. For example, compound 214 has the formula: [ka] The compound is identified as a specific PDE1 inhibitor represented by the formula:

[0273] As shown in the table below, this compound has potency against PDE1 at subnanomolar levels (IC of 0.058 nM against bovine brain PDE1 in the above assay). 50 ), which has higher selectivity than other PDE families:

[0274] [Table 1]

[0275] The compounds are also highly selective against a panel of 63 receptors, enzymes, and ion channels. These data and those of the other PDE1 inhibitors described herein are provided in Li et al., J. Med. Chem. 2016: 59, 1149-1164, the contents of which are incorporated herein by reference.

[0276] Example 2 Inhibition of monocyte-to-activated macrophage transition and interaction with ANP PDE1 is induced in inflammatory monocyte to activated macrophage transition mediated by GM-CSF, and this transition can be inhibited by PDE1 knockdown. Bender and Beavo, 2006 PNAS 103, 460-5. Atrial natriuretic peptide (ANP) increases cGMP levels by activating the ANP catalytic receptor, which stimulates intracellular guanylyl cyclase activity to convert GTP to cGMP. ANP has anti-inflammatory effects on macrophages and reduces the secretion of inflammatory mediators in macrophages. Kiemer, et al., Ann Rheum Dis. 2001 Nov; 60(Suppl 3): iii68-iii70. Specifically, ANP inhibits lipopolysaccharide (LPS)-induced expression of inducible nitric oxide synthase (iNOS) in macrophages, reduces NF-κB activation, and inhibits macrophage release of TNFα and interleukin 1β (IL1β), but not secretion of the anti-inflammatory cytokines IL10 and IL1 receptor antagonist (IL1ra).

[0277] The inventors have shown that there is a synergistic effect between ANP and PDE1 inhibition. Immortalized human promyelocytic cell line (HL60 from ATCC) is grown, differentiated and harvested as described in Bender, AT, and Beavo, JA, 2006, PNAS 103, 460-465. The cells are grown in HEPES-buffered RPMI1640 medium containing penicillin, streptomycin and 10% fetal bovine serum. HL60 cells are differentiated into macrophage-like cells using phorbol-12-myristate-13-acetate (PMA) at 100 nM for 3 days. After differentiation, cells are incubated with PDE1 inhibitor or vehicle (DMSO) from time 0. After 40 min, 5 μM ionomycin (calcium ionophore) is added. After 50 min, 100 nM ANP is added. After 60 min, cells are harvested. Total cGMP levels are measured using a competitive ELISA (Bender and Beavo, 2006).

[0278] Representative PDE1 inhibitors, as described in Example 20 of U.S. Pat. No. 8,273,750, have the following structures: [ka] (6aR,9aS)-3-(phenylamino)-5,6a,7,8,9,9a-hexahydro-5-methyl-2-(4-(trifluoromethyl)-benzyl)-cyclopenta[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one with the formula: is tested for its effect on cGMP levels in this system. Similar to compound 214, this compound is a potent and selective inhibitor of PDE1 (Ki=0.68nM in the bovine brain PDE1 assay described above). The cGMP levels induced in HL60 cells by treatment with 100nM ANP in conjunction with 100nM PDE1 inhibitor are higher than those induced by ANP alone or PDE1 inhibitor alone. Moreover, the cGMP levels obtained by combined treatment with ANP and PDE1 inhibitors are much higher than those obtained by combined treatment with ANP and the PDE1 / PDE5 inhibitor mixture SCH51866 (used at 5 μM). In this experiment, the calcium ionophore ionomycin (used at 5 μM) is used to increase intracellular calcium levels and counteract the increase in cGMP induced by ANP. The decrease in cGMP signal caused by the activation of PDE1 by ionomycin is synergistically prevented by the combination of PDE1 inhibitors with suboptimal levels of ANP. The addition of ionomycin has only a weak cGMP lowering effect when combined with ANP and PDE1 inhibitors.

[0279] Example 3 Effects of PDE1 inhibitors on microglia-derived cells Neuroinflammatory processes are primarily regulated by microglia. Microglia have an activation state somewhat similar to macrophages and are activated to release proinflammatory cytokines such as TNF-, IL-1β, and reactive oxygen species / reactive nitrogen species (ROS / NOS) in response to IFN-γ or lipopolysaccharide (LPS). They can be activated under other circumstances to release anti-inflammatory cytokines such as IL-10 and participate in tissue repair. As a model of microglial signaling, the immortalized mouse microglial cell line BV-2 is used. Stansley et al. Journal of Neuroinflammation 2012, 9:115.

[0280] BV2 cells are treated with lipopolysaccharide (LPS) and the level of PDE expression is measured using RNAseq analysis. The data is shown in Figure 1. "FPKM" stands for "fragment reads per kilobase of exon per million mapped reads." After treatment with LPS, an endotoxin associated with inflammatory responses, the level of PDE1B shows a relatively large increase in RNA expression when compared to other members of the PDE enzyme family. PDE1B is one of the phosphodiesterase subfamily that shows a large increase in RNA expression upon LPS administration.

[0281] BV2 cells were further cultured in the presence or absence of rolipram (a specific PDE4 inhibitor) and the formula: [ka] The expression of IL-16 is assessed by RNAseq analysis upon LPS stimulation in the presence or absence of compound 214, a specific PDE1 inhibitor, denoted by IL-16. In the presence of LPS + Rolipram, 209 mRNA transcripts are decreased compared to the presence of LPS alone, and in the presence of compound 214 + LPS, 138 transcripts are decreased compared to the presence of LPS alone. The overlap between the two sets is 48 transcripts. Similarly, in the presence of LPS + Rolipram, 156 transcripts are increased compared to the presence of LPS alone, and in the presence of compound 214 + LPS, 149 transcripts are increased compared to the presence of LPS alone. The overlap between the two sets is 45 transcripts.

[0282] In further experiments, analysis of expression in LPS-stimulated BV2 cells in the presence and absence of Compound 214 and Rolipram indicates that the differentially expressed genes for each pair (LPS vs. LPS+Rolipram, LPS vs. LPS+ITI-214) share approximately half of the genes with the highest significance. For example, the assay shows that there are 1240 genes significantly affected by Rolipram but not by Compound 214, 1463 genes significantly affected by Compound 214 but not by Rolipram, and only 683 genes affected by both, with only approximately half the overlap.

[0283] The relatively small overlap indicates that the effects of PDE1 inhibitors on these cells in response to LPS stimulation are very different from those of PDE4 inhibitors, which are often thought to be anti-inflammatory, but in this case the two inhibitors affect the expression of mostly quite different genes.

[0284] Furthermore, we compare the expression levels of PDEs in BV2 cells with those of mouse brain microglia as determined by RNAseq quantification of gene transcripts. As detailed in Table A, PDE1B is the second most abundant PDE transcript in freshly isolated mouse microglia and the most abundant PDE transcript in BV2 cells. Expression of PDE4B, PDE4A, PDE7A and PDE8a is also significant (≥0.7 FPKM / RPKM) in both cell types. Of the several PDE enzymes detected by RNA-Seq in BV2 cells, PDE1 is the only enzyme with the ability to hydrolyze both cAMP and cGMP. The relative abundance of PDE1B and PDE4 isozymes in BV2 cells potentially indicates that they are a suitable model for inhibitor studies (Table A).

[0285] [Table 2]

[0286] Example 4 Effect on IL1β expression in microglia-derived cells BV2 cells are incubated with (i) LPS (10 μg / ml), (ii) Compound 214 (10 μg / ml), or (iii) LPS and Compound 214. Levels of IL1β are measured using quantitative PCR of IL1β mRNA. IL1β is considered a marker of inflammation. Results are shown in Figure 2 (RQ: relative quantification of changes in gene expression between treated and control samples; *** p<0.01 vs. control, √ p<0.01 vs. LPS alone; ANOVA with Newman-Keuls post-hoc test). Thus, administration of a PDE1 inhibitor of the present invention significantly blunts the LPS-induced increase in IL1β expression in microglia-derived cells.

[0287] Example 5 –Effects on neuroinflammatory gene expression in BV2 cells Administration of the PDE1 inhibitor of the present invention (compound 214) at 10 μM significantly reduces the LPS-induced increase in the expression of inflammatory cytokines IL1β, TNFα and Ccl2 in BV2 cells, as measured by quantitative PCR, as described in Example 4 for IL1β. The PDE4 inhibitor rolipram shows a different profile, increasing IL1β expression while decreasing TNFα and Ccl2 expression. The data are shown in Figure 3a.

[0288] In another experiment, administration of a PDE1 inhibitor of the present invention (compound 214) significantly reduces or blunts LPS-induced changes in inflammatory markers in BV2 cells (Figure 3b). BV2 cells are pretreated with the compound, ITI-214, or the PDE4 inhibitor rolipram, then stimulated with 50 ng / ml LPS for 4 hours. Expression levels of TNF, IL1β, Ccl2, and IL6 are measured. Normalized mRNA levels are shown as change from vehicle (ΔΔCt) and compared using one-way ANOVA. Lines indicate mean values. *Significant difference from vehicle, #Significant difference from LPS. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. BV2 cells treated with 50 ng / ml LPS had elevated mRNA transcripts for TNF, IL1β, and Ccl2, three of the four cytokines studied in vivo. Treatment with ITI-214 (10 μM) significantly reduced the mRNA signals of TNF and Ccl2, and tended to reduce the mRNA signal of IL1β.

[0289] Example 6 – Inhibition of LPS-induced TNFα release from BV2 cells Inhibition of PDE1 reduces LPS-induced TNFα gene expression and release from BV2 cells.

[0290] TNFα release: TNFα levels are measured in BV2 conditioned medium and normalized to cellular protein levels. Inhibition of LPS-induced TNFα release from BV2 cells is shown in FIG. 4. The left panel shows BV2 cells treated with 10 μM compound 214 and 50 ng / ml LPS (one-way ANOVA, *p<0.05, vehicle n=16, LPS n=31, LPS+214 n=14). The right panel shows dose-dependent inhibition of LPS-induced TNFα release (50 ng / ml LPS stimulation) in response to compound 214 (measured as % inhibition of total LPS response per experiment).

[0291] TNFα gene expression: FIG. 5 shows that this dose-dependent decrease in TNFα release measured in the culture medium corresponds to a decrease in TNFα mRNA expression.

[0292] Example 7 –Effects on neuroinflammatory gene expression in BV2 cells and in vivo mouse striatum The effect of a selective PDE1 inhibitor (compound 214) in LPS-stimulated BV2 cells is tested by measuring changes in cytokine release using ELISA and changes in gene expression using RT-qPCR and RNA-Seq. (Experiment A (n=4): (1) vehicle; (2) 10 μM compound 214; (3) 50 ng / ml LPS; (4) 50 ng / ml LPS + 10 μM compound 214; Experiment B (n=2): (1) 50 ng / ml LPS; (2) 50 ng / ml LPS + 10 μM compound 214; (3) 50 ng / ml LPS + 10 μM rolipram (a known potent PDE4 inhibitor)). Test compounds were added first, LPS was added 1 hour later, and cells and / or media were harvested 5 hours after the start of the experiment.

[0293] PDE1 inhibition prevents LPS-induced increased TNFα release in BV2 cells. Similarly, inhibition of PDE1 reduces LPS-induced increases in TNFα, IL-1β, and Ccl2 mRNA expression by >50% in both BV2 cells and mice (p<0.01). To better understand the effects of PDE1 inhibition on resting and LPS-activated microglia, we use RNA-Seq to examine transcriptional regulation. We identify a subset of genes whose transcript expression is significantly altered by PDE1 inhibition. Using gene ontology software (AmiGO2), we find that these genes are significantly (p<0.05) enriched in cell migration and extracellular leakage pathways as well as inflammatory pathways. A portion of the genes induced by LPS are attenuated by inhibition of PDE1, all of which are significantly associated with inflammatory pathways (p<0.05). PDE4 inhibition attenuated a distinct subset of LPS-induced genes, indicating unique properties of this target (approximately 17% overlap with PDE1 inhibition).

[0294] Cells: BV2 mouse microglial cell line (ICLC, Italy) grown in 2% or 10% heat-inactivated FBS.

[0295] TNFα ELISA: Thermo Fisher mouse TNFα colorimetric, sandwich ELISA kit. Values ​​are interpolated from the standard curve. Dose-response is fitted with a 4-parameter logistic curve.

[0296] RTqPCR: RNA from BV2 cells purified using RNeasyKit (Qiagen) and RNA from mouse tissues using TRIzol (Ambion). TaqMan primer-probe assay from Thermo Fisher. mRNA levels in all conditions are normalized to GAPDH and vehicle controls (ΔΔCt). Data are statistically analyzed using one-way ANOVA with Bonferroni post-hoc test for multiple comparisons.

[0297] Our results show that inhibition of PDE1 modulates activity and reduces inflammatory gene expression in microglia, providing a rationale for using PDE1 inhibitors to treat toxic neuroinflammation.

[0298] RNASeq: BV2 cells are flash frozen, RNA isolated, libraries prepared using polyA selection, and 1x50bp single-read sequencing performed on an Illumina HiSeq 2500 in High Output mode (using V4 chemistry). Genes are mapped to the reference genome (GRCm38) using the CLC Genomics Server. On average, there are approximately 17 million reads per sample. Differential gene expression analysis is performed using DESeq2 software (Bioconductor.org). Differentially expressed genes (p<0.01, Wald test) are reported as log2 (fold change).

[0299] The table below summarizes the initial results of neuroinflammatory biomarker expression in both BV2 cells and mouse striatum subjected to LPS challenge in the presence or absence of a PDE1 inhibitor (compound 214) or a PDE4 inhibitor (rolipram). Results are based on evaluation of samples using Q-PCR.

[0300] [Table 3]

[0301] Administration of the PDE1 inhibitors of the present invention correlates with reduced or unchanged expression of the biomarkers IL1β, TNF-α and Ccl2 compared to samples treated with LPS alone. Interestingly, the anti-inflammatory profile of PDE1 inhibitors is quite different from that of PDE4 inhibitors.

[0302] Data from a further experiment measuring the effect of PDE1 inhibition on inflammatory gene expression in mouse striatum are shown in Figure 6. Adult mice are treated with vehicle (white bars), LPS 500 μg / kg sc (gray bars), or 10 mg / kg (compound 214) ip and LPS 500 μg / kg sc (black bars) for 2 hours (n=4). Striatal tissue is analyzed for TNF, IL1β, Ccl2 and IL6 mRNA levels. Expression levels are shown as the change in Q-PCR signal from vehicle (ΔΔCt) and compared using ANOVA. * p<0.05, ** p<0.01, *** p<0.001.

[0303] Applicants have used quantitative PCR to measure mRNA levels of four common inflammatory markers (TNF, IL1β, Ccl2 and IL6) (Figure 7). In adult mice treated with LPS 500 μg / kg sc for 2 hours, the mRNA expression levels of all four markers are significantly increased as measured in tissue samples isolated from the striatum (Figure 7). A dose of 10 mg / kg (compound 214) delivered ip attenuates the expression of TNF and Ccl2. In this experiment, the levels of IL1-β and IL6 tended to decrease as well, but did not reach significance.

[0304] Example 8 –Effect on BV2 chemotaxis Dying neurons lose membrane integrity and release ATP, which is rapidly hydrolyzed to ADP, a chemotactic signal to microglia to migrate to the site of injury, where they phagocytose cellular debris. The target of ADP chemotaxis in microglia and in BV2 cells, a microglial cell line, is the Gi / o-coupled purinergic receptor P2Y12. This G protein typically inhibits adenylyl cyclase and thus cAMP formation, but activation of P2RY12 by ADP in this system has been reported to increase cAMP. When cAMP levels are enhanced beyond those caused by ADP, such as by the addition of forskolin, chemotaxis to ADP is inhibited. In this system, cAMP phosphorylates the focal adhesion-associated protein vasodilator-stimulated phosphoprotein (VASP) via activation of protein kinase A (PKA), and enhancement of cAMP or prolonged phosphorylation by inhibition of PP2A inhibits migration.

[0305] The first study was performed to test the ability of compound 214 (shown in Example 1 above) to inhibit chemotaxis of BV2 cells. Chemotaxis to 100M ADP was measured in a Boyden chamber system against vehicle control for 4 hours. BV2 cells were added to the top chamber of a 5 μm-pore Boyden chamber, and 100 μM ADP or vehicle was added to the bottom chamber and incubated at 37° C., 5% CO2 for 4 hours. The curves were fitted to a four-parameter logarithmic equation with the following constraints: top >80%, bottom <20%. It was found that inhibition of PDE1 by ITI-214 indeed inhibits ADP-induced chemotaxis of BV2 cells in the Boyden chamber system, where cells migrate from the top chamber to the bottom chamber containing the chemoattractant ADP. Raw fluorescence counts (relative fluorescence units or RFU), which represent the number of cells in the bottom chamber, were used to calculate the control condition, as shown in the left panel of FIG. 7A. Vehicle conditions represent minimal migration in the absence of ADP. Maximum migration was shown as the 100 μM ADP condition. As shown in the right panel of Figure 7A, compound 214 dose-dependently reduced the chemotaxis of BV2 cells to 100 μM ADP.

[0306] To confirm that ADP-induced migration in our system is mediated by P2Y12 receptors, we further demonstrated dose-dependent inhibition of migration using two P2Y12 inhibitors as shown in Figure 7B. The P2Y12 inhibitors used were AR-C66096 (open circles, demonstrated an IC50 of 6.9 nM) and AR-C69931 (closed circles, demonstrated an IC50 of 0.4 nM), which inhibited ADP-induced migration in the Boyden chamber system. The measured potency correlates with the demonstrated IC50 values. These results indicate a critical role for P2Y12 receptors in the migration response.

[0307] In further experiments, BV2 cells were treated with compound 214 or IBMX for 30 min and then stimulated with ADP for 5 min. cAMP levels were normalized to cell number. Western cell lysates were blotted with an antibody against phosphorylated VASP at S157 and the intensity of the resulting bands was measured (as raw signal). PDE1 inhibition with compound 214 in BV2 cells significantly increased the ADP-induced increase in cAMP measured by ELISA and in P-VASP at serine 157 measured by Western blot (Figure 8). Consistent with the hypothesis that PDE1 is important under stimulated conditions, there was no effect of PDE1 inhibition at baseline. IBMX, a pan-PDE inhibitor, increased cAMP and P-VASP levels under baseline conditions, suggesting that other PDE families are important for maintaining homeostasis. Compound 214 prevents ADP-induced chemotaxis of BV2 cells by enhancing cAMP levels and phosphorylation of VASP. PDE1 activity (sensitive to ITI-214), like cAMP, appears to contribute approximately 50% of total PDE activity (sensitive to IBMX) under stimulated conditions but none at baseline. The dose dependence of the increase in cAMP is shown in Figure 9.

[0308] The above results were also replicated in primary cultured microglia isolated from P2 rat whole brains (Figure 10). Microglia were cultured for 12 days in serum-free medium containing TGFb2, IL34 and cholesterol. The cells maintained characteristics in culture consistent with quiescent microglia-like cells, staining positively for Iba1 and maintaining a branched morphology. Addition of 1 μM ITI-214 significantly enhanced the increase in VASP phosphorylation detected after 5 min treatment with 100 μM ADP, similar to BV2 cells, but had little effect under basal conditions (Figure 10). Reproduction of these data in microglial cells suggests that the findings in BV2 cells may be representative of microglial cell responses.

[0309] Example 9 –Effect of PDE1 treatment alone and in combination with anti-PD-1 treatment on mouse colorectal cancer cells The effect of administration of compound 214, either alone or in combination with a subthreshold dose of a checkpoint inhibitor, on tumor size was studied. Mice were implanted subcutaneously with CT26 colorectal cancer cells. Control mice were administered 150 μg of IgG (isotype). The remaining mice were administered 1 mg of compound 214, 5 days per week, starting on day 7; or 150 μg of anti-PD-1 (RMP1-14 monoclonal antibody, in PBS carrier at pH 3.5) on days 7, 11, 14, and 17; or both compound 214 and anti-PD-1. The effect on terminal tumor volume is shown in Figure 11. Compound 214 administered alone and in combination with anti-PD-1 antibody resulted in responders (i.e., tumor volumes of 500 mm 3 It was shown that the proportion of those with a pulmonary circulation below 100°C increased.

[0310] Analysis of diseased tissues showed that compound 214 also significantly reduced the number of macrophages (CD45 positive) in the tumor microenvironment when administered ip at a concentration of 50 mg / kg once daily either alone or in combination with an anti-PD1 antibody, as shown in Figure 12. Overall, compound 214 has been shown to have a sustained effect on the tumor microenvironment, reducing tumor volume and coinciding with a reduction in macrophage infiltration.

Claims

1. (A) cancer or tumor recruitment of immune cells, such as macrophages (e.g., TAMs or MAMs) or microglia, e.g., chemokine-mediated recruitment, e.g., CCL2-mediated recruitment; (B) a tumor or cancer metastasis, such as a TAM-associated or MAM-associated metastasis; (C) tumor or cancer angiogenesis, e.g., TAM-associated or MAM-associated angiogenesis; (D) disruption of tumor or cancer immune surveillance, e.g., disruption of TAM-associated or MAM-associated immune surveillance.

5. A method for treating cancer or tumors by inhibiting one or more of the following:

2. 3. The method of claim 1 or 2, wherein the condition is a tumor.

3. The tumor may be an acoustic neuroma, astrocytoma, chordoma, lymphoma (e.g., CNS lymphoma, Hodgkin's lymphoma, or non-Hodgkin's lymphoma), craniopharyngioma, glioma (e.g., brain stem glioma, ependymoma, mixed glioma, optic nerve glioma), subependymoma, medulloblastoma, meningioma, metastatic brain tumor, oligodendroglioma, pituitary tumor, primitive neuroectodermal tumor (PNET), Schwannoma, adenoma (e.g., basophilic adenoma, acidophilic adenoma, chromophobe adenoma, parathyroid adenoma, pancreatic islet adenoma, fibroadenoma), fibroid (fibrous histiocytoma), fibroma, hemangioma, lipoma (e.g., angiolipoma, myelolipoma, fibrolipoma, spindle cell lipoma, brown lipoma, atypical lipoma), myxoma, osteoma, preleukemia, rhadomyoma, papilloma, seborrheic keratosis, skin adnexal tumor, hepatic adenoma, renal tubular adenoma, bile duct adenoma, transitional cell papilloma, hydatidiform mole, ganglioneuroma, meningioma, schwannoma, neurofibroma, C-cell hyperplasia, pheochromocytoma, insulinoma, gastrinoma, carcinoid, chemodectoma, paraganglioma, nevus, actinic keratosis, cervical dysplasia, metaplasia (e.g., pulmonary metaplasia), leukoplakia, hemangioma, lymphangioma, carcinoma (e.g., squamous cell carcinoma, epidermoid carcinoma, adenocarcinoma, hepatoma, hepatocellular carcinoma, renal cell carcinoma, cholangiocarcinoma, transitional cell carcinoma, embryonal cell carcinoma, cell carcinoma), parathyroid carcinoma, medullary thyroid carcinoma, bronchial carcinoid, oat cell carcinoma, islet cell carcinoma, malignant carcinoid, Merkel cell tumor, colon carcinoma), sarcomas (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, malignant fibrous histiocytoma, hemangiosarcoma, angiosarcoma, lymphangiosarcoma, leiomyosarcoma, rhabdomyosarcoma, neurofibrosarcoma), blastomas (e.g., medulloblastoma and glioblastoma, types of brain tumors, retinoblastoma, tumors of the retina of the eye, osteoblastoma, bone tumor, neuroblastoma), germ cell tumors, mesothelioma, malignant skin adnexal tumors, hypernephroma, seminoma, glioma, malignant meningioma, malignant schwannoma, malignant pheochromocytoma, malignant paraganglioma, melanoma, Merkel cell neoplasm 20. The method of any of the preceding claims, wherein the cancer is selected from one or more of: sarcoma phyllodes (cell neoplasm), cystosarcoma phylloides, or Wilms' tumor.

4. 13. The method of any of the above claims, comprising administering a checkpoint inhibitor selected from one or more of an inhibitor of CTLA-4, PD-1 and / or PD-L1.

5. 2. The method of any of the preceding claims, comprising administering a checkpoint inhibitor comprising one or more members selected from nivolumab, pembrolizumab, cemiplimab, ipilimumab, avelumab, durvalumab, atezolizumab, and spartalizumab.

6. 20. The method of any preceding claim, wherein the subject is suffering from a systemic inflammatory response, a gastroenteritis-related disorder, an endocrine inflammation-related disorder, a dermatological inflammation-related disorder, an ophthalmological inflammation-related disorder, a neurological inflammation-related disorder, a hematological inflammation-related disorder, a genitourinary inflammation-related disorder, a respiratory inflammation-related disorder, a musculoskeletal inflammation-related disorder, a cardiac inflammation-related disorder, or a defined systemic inflammation-related disorder.

7. A method for preventing or alleviating a disease, disorder, or adverse effect resulting from checkpoint inhibitor therapy, comprising administering to a subject in need of such prevention or alleviation a pharma- ceutically acceptable amount of a PDE1 inhibitor (i.e., a PDE1 inhibitor represented by Formula I, Ia, II, III, IV, V and / or VI).

8. 8. The method of claim 7, wherein checkpoint inhibitor therapy is administered for the treatment of cancer or tumor.

9. 9. The method of claim 7 or 8, wherein the checkpoint inhibitor is an inhibitor of CTLA-4, PD-1 and / or PD-L1; e.g., the checkpoint inhibitor comprises one or more members selected from nivolumab, pembrolizumab, cemiplimab, ipilimumab, avelumab, durvalumab, atezolizumab and spartalizumab.

10. 10. The method of any of claims 7 to 9, wherein the disease, disorder or adverse effect as a result of administration of checkpoint inhibitor therapy is a systemic inflammatory response, a gastroenteritis-related disorder, an endocrine inflammation-related disorder, a dermatological inflammation-related disorder, an ophthalmological inflammation-related disorder, a neurological inflammation-related disorder, a hematological inflammation-related disorder, a genitourinary inflammation-related disorder, a respiratory inflammation-related disorder, a musculoskeletal inflammation-related disorder, a cardiac inflammation-related disorder, or a defined systemic inflammation-related disorder.

11. A method for inhibiting macrophage or microglia recruitment to metastatic cells, comprising administering to a subject in need of such inhibition a pharma- ceutically acceptable amount of a PDE1 inhibitor (i.e., a PDE1 inhibitor represented by Formula I, Ia, II, III, IV, V and / or VI).

12. 12. The method of claim 11, wherein macrophage or microglia recruitment to metastatic cells is mediated, at least in part, by CCL2.

13. 13. The method of claim 11 or 12, wherein the PDE1 inhibitor is administered in combination with a checkpoint inhibitor, e.g., the checkpoint inhibitor is an inhibitor of CTLA-4, PD-1 and / or PD-L1; e.g., the checkpoint inhibitor comprises one or more members selected from nivolumab, pembrolizumab, cemiplimab, ipilimumab, avelumab, durvalumab, atezolizumab and spartalizumab.

14. The PDE1 inhibitor (A) A compound of formula I: in free form, in the form of a salt or in prodrug form, including its enantiomers, diastereoisomers and racemates: 【Chemistry 1】 [In the formula, (i) R 1 is H or C 1-4 alkyl (e.g., methyl); (ii) R 4 is H or C 1-4 alkyl, R 2 and R 3 are independently H or C 1-4 Alkyl (e.g., R 2 and R 3 are both methyl, or R 2 is H, and R 3 is isopropyl), aryl, heteroaryl, (optionally hetero)arylalkoxy, or (optionally hetero)arylalkyl; or R 2 is H, R 3 and R 4 together form a dimethylene bridge, a trimethylene bridge or a tetramethylene bridge (preferably R 3 and R 4 together have a cis configuration, e.g., R 3 and R 4 have the R and S configurations, respectively; (iii) R 5 is a substituted heteroarylalkyl, e.g., substituted with haloalkyl; or R 5 is attached to one of the nitrogens of the pyrazolo moiety of formula I, 【Chemistry 2】 wherein X, Y and Z are independently N or C; R 8 , R 9 , R 11 and R 12 are independently H or halogen (e.g., Cl or F), and R 10 is halogen, alkyl, cycloalkyl, haloalkyl (e.g., trifluoromethyl), aryl (e.g., phenyl), heteroaryl (e.g., pyridyl (e.g., pyrid-2-yl), or thiadiazolyl (e.g., 1,2,3-thiadiazol-4-yl) optionally substituted with halogen), diazolyl, triazolyl, tetrazolyl, arylcarbonyl (e.g., benzoyl), alkylsulfonyl (e.g., methylsulfonyl), heteroarylcarbonyl, or alkoxycarbonyl; with the proviso that when X, Y, or Z is nitrogen, then R 8 , R 9 Or R 10 does not exist) The part indicated by: (iv) R 6 is H, alkyl, aryl, heteroaryl, arylalkyl (e.g., benzyl), arylamino (e.g., phenylamino), heteroarylamino, N,N-dialkylamino, N,N-diarylamino, or N-aryl-N-(arylalkyl)amino (e.g., N-phenyl-N-(1,1′-biphen-4-ylmethyl)amino); (v) n is 0 or 1; (vi) When n is 1, A is -C(R 13 R 14 )--wherein R 13 and R 14 are independently H or C 1-4 alkyl, aryl, heteroaryl, (optionally hetero)arylalkoxy or (optionally hetero)arylalkyl; (B) A compound of formula II, in free form, in salt form or in prodrug form: 【Chemistry 3】 [In the formula, (i) X is C 1-6 alkylene (e.g., methylene, ethylene, or prop-2-yn-1-ylene); (ii) Y is a single bond, alkynylene (e.g., -C≡C-), arylene (e.g., phenylene), or heteroarylene (e.g., pyridylene); (iii) Z is H, aryl (e.g., phenyl), heteroaryl (e.g., pyridyl, e.g., pyrid-2-yl), halo (e.g., F, Br, Cl), haloC 1-6 Alkyl (e.g., trifluoromethyl), —C(O)—R 1 , -N(R 2 )(R 3 ), or C, which may contain at least one atom selected from the group consisting of N or O 3-7 cycloalkyl (e.g., cyclopentyl, cyclohexyl, tetrahydro-2H-pyran-4-yl, or morpholinyl); (iv) R 1 is C 1-6 Alkyl, haloC 1-6 Alkyl, —OH or —OC 1-6 Alkyl (e.g., —OCH 3 ) and (v) R 2 and R 3 are independently H or C 1-6 is alkyl; (vi) R 4 and R 5 are independently H, C 1-6 Alkyl, or one or more halo (e.g., fluorophenyl, e.g., 4-fluorophenyl), hydroxy (e.g., hydroxyphenyl, e.g., 4-hydroxyphenyl or 2-hydroxyphenyl) or C 1-6 aryl (e.g., phenyl) optionally substituted with alkoxy; (vii) wherein X, Y and Z are independently one or more halo (e.g., F, Cl or Br), C 1-6 Alkyl (e.g., methyl), haloC 1-6 For example, Z may be substituted with one or more halo (e.g., 6-fluoropyrid-2-yl, 5-fluoropyrid-2-yl, 6-fluoropyrid-2-yl, 3-fluoropyrid-2-yl, 4-fluoropyrid-2-yl, 4,6-dichloropyrid-2-yl), haloC 1-6 Alkyl (e.g., 5-trifluoromethylpyrid-2-yl) or C 1-6 -heteroaryl, such as pyridyl, substituted with alkyl (e.g., 5-methylpyrid-2-yl), or Z is aryl, such as phenyl, substituted with one or more halo (e.g., 4-fluorophenyl); (C) a compound of formula III, in free or salt form: 【Chemistry 4】 [In the formula, (i) R 1 is H or C 1-4 alkyl (e.g., methyl or ethyl); (ii) R 2 and R 3 are independently H or C 1-6 alkyl (e.g., methyl or ethyl); (iii) R 4 is H or C 1-4 alkyl (e.g., methyl or ethyl); (iv) R 5 are independently -C(=O)-C 1-6 Alkyl (e.g., -C(=O)-CH 3 ) and C 1-6 -aryl (e.g., phenyl) optionally substituted with one or more groups selected from -hydroxyalkyl (e.g., 1-hydroxyethyl); (v) R 6 and R 7 are independently H or independently C 1-6 Aryl (e.g., phenyl) optionally substituted with one or more groups selected from alkyl (e.g., methyl or ethyl) and halogen (e.g., F or Cl), e.g., unsubstituted phenyl, or phenyl substituted with one or more halogen (e.g., F), or one or more C 1-6 Phenyl substituted with alkyl and one or more halogens, or one C 1-6 phenyl substituted with alkyl and one halogen, such as 4-fluorophenyl or 3,4-difluorophenyl or 4-fluoro-3-methylphenyl; (vi) n is 1, 2, 3 or 4; (D) Formula IV, in free or salt form 【Chemistry 5】 [In the formula, (vi) R 1 is C 1-4 Alkyl (e.g., methyl or ethyl), or -NH(R 2 ) (where R 2 is phenyl optionally substituted with halo (e.g., fluoro), e.g., 4-fluorophenyl; (vii) X, Y and Z are independently N or C; (viii) R 3 , R 4 and R 5 are independently H or C 1-4 alkyl (e.g., methyl); or R 3 is H, and R 4 and R 5 together form a trimethylene bridge (preferably R 4 and R 5 together have a cis configuration, e.g., R 4 and R 5 each of the carbons carrying the R and S configurations; (ix) R 6 , R 7 and R 8 is, independently, H. C 1-4 Alkyl (e.g., methyl), pyrid-2-yl substituted with hydroxy, or -S(O) 2 -NH 2 and However, when X, Y and / or Z are N, R 6 , R 7 and / or R 8 does not exist; and when X, Y and Z are all C, then R 6 , R 7 Or R 8 At least one of is -S(O) 2 -NH 2 or pyrid-2-yl substituted with hydroxy; (E) A compound of formula 1a: in free form, in the form of a pharma- ceutically acceptable salt or in prodrug form, including its enantiomers, diastereoisomers and racemates: 【Chemistry 6】 [In the formula, (v) R 2 and R 5 is independently H or hydroxy; R 3 and R 4 together form a trimethylene or tetramethylene bridge, preferably 3 and R 4 the carbons carrying R and S configurations, respectively; or R 2 and R 3 are each methyl; R 4 and R 5 are each H; or R 2 , R 4 and R 5 is H, and R 3 is isopropyl, preferably R 3 the carbon bearing the has the R configuration; (vi) R 6 is optionally halo-substituted phenylamino, optionally halo-substituted benzylamino, C 1-4 Alkyl, or C 1-4 alkylsulfide; for example, phenylamino or 4-fluorophenylamino; (vii) R 10 is C 1-4 alkyl, methylcarbonyl, hydroxyethyl, carboxylic acid, sulfonamide, (optionally halo- or hydroxy-substituted)phenyl, (optionally halo- or hydroxy-substituted)pyridyl (e.g., 6-fluoropyrid-2-yl), or thiadiazolyl (e.g., 1,2,3-thiadiazol-4-yl); X and Y are independently C or N; (F) Formula V, in free or salt form 【Chemistry 7】 [In the formula, (iv) R 1 is -NH(R 4 ), where R 4 is phenyl optionally substituted with halo (e.g., fluoro), e.g., 4-fluorophenyl; (v) R 2 is H or C 1-6 alkyl (e.g., methyl, isobutyl, or neopentyl); (vi) R 3 is -SO 2 N.H. 2 or -COOH; and / or (G) Formula V, in free or salt form 【Chemistry 8】 [In the formula, (iv) R 1 is -NH(R 4 ), where R 4 is phenyl optionally substituted with halo (e.g., fluoro), e.g., 4-fluorophenyl; (v) R 2 is H or C 1-6 alkyl (e.g., methyl or ethyl); (vi) R 3 is H, halogen (e.g., bromo), C 1-6 alkyl (e.g., methyl), aryl optionally substituted with halogen (e.g., 4-fluorophenyl), heteroaryl optionally substituted with halogen (e.g., 6-fluoropyrid-2-yl or pyrid-2-yl), or acyl (e.g., acetyl). The method according to any of the preceding claims, wherein the compound is selected from:

15. The PDE1 inhibitor is selected from the group consisting of the following in free form or in pharma- ceutically acceptable salt form: 【Chemistry 9】 13. The method according to any of the preceding claims, selected from any of the following:

16. The PDE1 inhibitor is in free form or in the form of a pharma- ceutically acceptable salt, e.g., in the form of a monophosphate. 【Chemistry 10】 2. The method of claim 1, wherein

17. The PDE1 inhibitor is, in free form or in the form of a pharma- ceutically acceptable salt, 【Chemistry 11】 2. The method of claim 1, wherein

18. A PDE1 inhibitor (e.g. a compound of formula I, Ia, II, III, IV, V and / or VI) for use in the method of any preceding claim.

19. A pharmaceutical combination therapy comprising a pharma- ceutical effective amount of a PDE1 inhibitor (e.g., a compound of Formula I, Ia, II, III, IV, V and / or VI) and a checkpoint inhibitor, e.g. for use in a method of any of the above claims.

Citation Information

Patent Citations

  • Organic compounds

    WO2016022893A1